CN114106088A - Bromomethylpyrazine-based drug conjugates and ADCs - Google Patents
Bromomethylpyrazine-based drug conjugates and ADCs Download PDFInfo
- Publication number
- CN114106088A CN114106088A CN202110466799.3A CN202110466799A CN114106088A CN 114106088 A CN114106088 A CN 114106088A CN 202110466799 A CN202110466799 A CN 202110466799A CN 114106088 A CN114106088 A CN 114106088A
- Authority
- CN
- China
- Prior art keywords
- antibody
- formula
- group
- cancer
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 229940079593 drug Drugs 0.000 title claims abstract description 34
- VNMORBLLLTZLLT-UHFFFAOYSA-N 2-(bromomethyl)pyrazine Chemical compound BrCC1=CN=CC=N1 VNMORBLLLTZLLT-UHFFFAOYSA-N 0.000 title abstract description 7
- 229940049595 antibody-drug conjugate Drugs 0.000 claims abstract description 59
- 239000000611 antibody drug conjugate Substances 0.000 claims abstract description 48
- 150000001875 compounds Chemical class 0.000 claims description 144
- -1 p-aminobenzyloxy Chemical group 0.000 claims description 33
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 30
- 230000027455 binding Effects 0.000 claims description 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 26
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 26
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 26
- 239000000427 antigen Substances 0.000 claims description 23
- 102000036639 antigens Human genes 0.000 claims description 23
- 108091007433 antigens Proteins 0.000 claims description 23
- 101150029707 ERBB2 gene Proteins 0.000 claims description 22
- 239000012634 fragment Substances 0.000 claims description 21
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 17
- 235000001014 amino acid Nutrition 0.000 claims description 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- 229940024606 amino acid Drugs 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 15
- SLURUCSFDHKXFR-WWMWMSKMSA-N (7s,9s)-7-[[(1s,3r,4as,9s,9ar,10as)-9-methoxy-1-methyl-3,4,4a,6,7,9,9a,10a-octahydro-1h-pyrano[1,2][1,3]oxazolo[3,4-b][1,4]oxazin-3-yl]oxy]-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound O=C1C2=CC=CC(OC)=C2C(=O)C(C(O)=C23)=C1C(O)=C3C[C@@](O)(C(=O)CO)C[C@@H]2O[C@H]1C[C@@H]2N3CCO[C@H](OC)[C@H]3O[C@@H]2[C@H](C)O1 SLURUCSFDHKXFR-WWMWMSKMSA-N 0.000 claims description 14
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 14
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 13
- 125000003277 amino group Chemical group 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- NJNWCIAPVGRBHO-UHFFFAOYSA-N 2-hydroxyethyl-dimethyl-[(oxo-$l^{5}-phosphanylidyne)methyl]azanium Chemical group OCC[N+](C)(C)C#P=O NJNWCIAPVGRBHO-UHFFFAOYSA-N 0.000 claims description 12
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 12
- 239000004472 Lysine Substances 0.000 claims description 12
- 229930126263 Maytansine Natural products 0.000 claims description 12
- 125000005997 bromomethyl group Chemical group 0.000 claims description 12
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 12
- 229940127093 camptothecin Drugs 0.000 claims description 12
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 12
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 claims description 12
- 125000006239 protecting group Chemical group 0.000 claims description 12
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 11
- 125000003368 amide group Chemical group 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 10
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 9
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 9
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 9
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 9
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 229960003104 ornithine Drugs 0.000 claims description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical group CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 claims description 7
- 239000004471 Glycine Substances 0.000 claims description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 7
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 239000004474 valine Substances 0.000 claims description 7
- 108010073969 valyllysine Proteins 0.000 claims description 7
- 102000035195 Peptidases Human genes 0.000 claims description 6
- 108091005804 Peptidases Proteins 0.000 claims description 6
- 125000004419 alkynylene group Chemical group 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 125000005647 linker group Chemical group 0.000 claims description 6
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 5
- FNXSYBOHALPRHV-ONGXEEELSA-N Gly-Val-Lys Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN FNXSYBOHALPRHV-ONGXEEELSA-N 0.000 claims description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 5
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 125000004450 alkenylene group Chemical group 0.000 claims description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
- 201000004101 esophageal cancer Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 230000001575 pathological effect Effects 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 4
- PLXLYXLUCNZSAA-QLXKLKPCSA-N CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=C(F)C(C)=C4CC[C@H](NC(=O)CO)C3=C14)C2=O Chemical compound CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=C(F)C(C)=C4CC[C@H](NC(=O)CO)C3=C14)C2=O PLXLYXLUCNZSAA-QLXKLKPCSA-N 0.000 claims description 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 4
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 4
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 4
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 claims description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 229930192392 Mitomycin Natural products 0.000 claims description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 229960001230 asparagine Drugs 0.000 claims description 4
- 235000009582 asparagine Nutrition 0.000 claims description 4
- 229960004117 capecitabine Drugs 0.000 claims description 4
- 235000013477 citrulline Nutrition 0.000 claims description 4
- 229960002173 citrulline Drugs 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 4
- 229960000684 cytarabine Drugs 0.000 claims description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 4
- 229960000975 daunorubicin Drugs 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 claims description 4
- 229950005454 doxifluridine Drugs 0.000 claims description 4
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- 229960001904 epirubicin Drugs 0.000 claims description 4
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 claims description 4
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 claims description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 4
- 229960005420 etoposide Drugs 0.000 claims description 4
- 229960000390 fludarabine Drugs 0.000 claims description 4
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 4
- 229960002949 fluorouracil Drugs 0.000 claims description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 4
- 229960005277 gemcitabine Drugs 0.000 claims description 4
- 229960004768 irinotecan Drugs 0.000 claims description 4
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 4
- 229960001924 melphalan Drugs 0.000 claims description 4
- 229960000485 methotrexate Drugs 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 229960004857 mitomycin Drugs 0.000 claims description 4
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 4
- 229960001156 mitoxantrone Drugs 0.000 claims description 4
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 claims description 4
- 229960001420 nimustine Drugs 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 229960000303 topotecan Drugs 0.000 claims description 4
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 4
- 229960004528 vincristine Drugs 0.000 claims description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 4
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 229950004354 phosphorylcholine Drugs 0.000 claims description 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 108091005502 Aspartic proteases Proteins 0.000 claims description 2
- 102000035101 Aspartic proteases Human genes 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 102000005927 Cysteine Proteases Human genes 0.000 claims description 2
- 108010005843 Cysteine Proteases Proteins 0.000 claims description 2
- 108010016626 Dipeptides Proteins 0.000 claims description 2
- 102000013382 Gelatinases Human genes 0.000 claims description 2
- 108010026132 Gelatinases Proteins 0.000 claims description 2
- 108091005503 Glutamic proteases Proteins 0.000 claims description 2
- 108010006035 Metalloproteases Proteins 0.000 claims description 2
- 102000005741 Metalloproteases Human genes 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 108091005501 Threonine proteases Proteins 0.000 claims description 2
- 102000035100 Threonine proteases Human genes 0.000 claims description 2
- 208000006593 Urologic Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 125000006356 alkylene carbonyl group Chemical group 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 208000024348 heart neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical group C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims description 2
- 235000019833 protease Nutrition 0.000 claims description 2
- 235000019419 proteases Nutrition 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000003073 testicular leukemia Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 1
- 239000000562 conjugate Substances 0.000 abstract description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 93
- 238000006243 chemical reaction Methods 0.000 description 84
- 239000012071 phase Substances 0.000 description 50
- 238000003786 synthesis reaction Methods 0.000 description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 40
- 230000015572 biosynthetic process Effects 0.000 description 38
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 32
- 238000002360 preparation method Methods 0.000 description 30
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 28
- 239000000243 solution Substances 0.000 description 26
- 238000000034 method Methods 0.000 description 24
- 238000004128 high performance liquid chromatography Methods 0.000 description 22
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 20
- 239000002609 medium Substances 0.000 description 19
- 239000000047 product Substances 0.000 description 18
- 230000002441 reversible effect Effects 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 14
- 239000002994 raw material Substances 0.000 description 12
- 125000003118 aryl group Chemical group 0.000 description 11
- 229960003646 lysine Drugs 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 10
- 238000004587 chromatography analysis Methods 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- 239000012043 crude product Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 229960001153 serine Drugs 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 229940125904 compound 1 Drugs 0.000 description 7
- 125000000623 heterocyclic group Chemical group 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000012295 chemical reaction liquid Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 229960002449 glycine Drugs 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 6
- 229960004295 valine Drugs 0.000 description 6
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 5
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- VZGDMQKNWNREIO-UHFFFAOYSA-N carbon tetrachloride Substances ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 229940126214 compound 3 Drugs 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000004576 sand Substances 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 231100000491 EC50 Toxicity 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 3
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- HOYRZHJJAHRMLL-UHFFFAOYSA-N 2,6-dinitro-p-cresol Chemical compound CC1=CC([N+]([O-])=O)=C(O)C([N+]([O-])=O)=C1 HOYRZHJJAHRMLL-UHFFFAOYSA-N 0.000 description 2
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 2
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 102000030431 Asparaginyl endopeptidase Human genes 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 108010055066 asparaginylendopeptidase Proteins 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229960002433 cysteine Drugs 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- CAWHJQAVHZEVTJ-UHFFFAOYSA-N methylpyrazine Chemical compound CC1=CN=CC=N1 CAWHJQAVHZEVTJ-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 229910052717 sulfur Chemical group 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical class CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- KGRVJHAUYBGFFP-UHFFFAOYSA-N 2,2'-Methylenebis(4-methyl-6-tert-butylphenol) Chemical compound CC(C)(C)C1=CC(C)=CC(CC=2C(=C(C=C(C)C=2)C(C)(C)C)O)=C1O KGRVJHAUYBGFFP-UHFFFAOYSA-N 0.000 description 1
- LHKFFORGJVELPC-UHFFFAOYSA-N 2,3-bis(bromomethyl)quinoxaline Chemical compound C1=CC=C2N=C(CBr)C(CBr)=NC2=C1 LHKFFORGJVELPC-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- AJYKJVCIKQEVCF-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrazin-2-one Chemical class CC1=CNC(=O)C(C)=N1 AJYKJVCIKQEVCF-UHFFFAOYSA-N 0.000 description 1
- WSNKEJIFARPOSQ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(1-benzothiophen-2-ylmethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC3=C(S2)C=CC=C3)C=CC=1 WSNKEJIFARPOSQ-UHFFFAOYSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- RYAOJUMWLWUGNW-QMMMGPOBSA-N Gly-Val-Gly Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O RYAOJUMWLWUGNW-QMMMGPOBSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- ZFOMKMMPBOQKMC-KXUCPTDWSA-N L-pyrrolysine Chemical compound C[C@@H]1CC=N[C@H]1C(=O)NCCCC[C@H]([NH3+])C([O-])=O ZFOMKMMPBOQKMC-KXUCPTDWSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 125000004652 decahydroisoquinolinyl group Chemical group C1(NCCC2CCCCC12)* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000000232 haloalkynyl group Chemical group 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
Abstract
The invention provides bromomethylpyrazine-based drug conjugates and ADCs. The structural formula of the drug conjugate is shown as the formula I: r1‑L1‑L2‑R2-D, wherein R1、L1、L2、R2And D is as described herein. The drug conjugate can be connected with an antibody to prepare the antibody drug conjugate.
Description
Technical Field
The invention relates to bromomethylpyrazine-based drug conjugates and ADCs.
Background
An antibody-drug conjugate (ADC) is prepared by linking a bioactive small molecule drug to a monoclonal antibody through a chemical linkage, and the monoclonal antibody is used as a carrier to target and transport the small molecule drug to a target cell. In the target cells, the drug is released, thereby achieving the therapeutic objective.
ADC drug structures are complex and there are large differences between different ADC drug designs. Even different drugs at the same target point have obvious toxicity differences due to differences in recognition sites, ligation sites, linkers and small molecules ligated.
Disclosure of Invention
In a first aspect, the present invention provides a compound having the structure shown in formula I below:
R1-L1-L2-R2-D (I)
in the formula (I), the compound is shown in the specification,
R1selected from any of the following structural formulas:
wherein R is6Is bromomethyl, i.e. CH2Br-, o is 1 or 2, the wavy line represents1The connection position of (a);
L1is-La-Lb-, wherein LaIs C1-C6 alkylene, C2-C6 alkenylene, C2-C6 alkynylene or- (CH)2)p-CONH-[CH2CH2-O]q-(CH2)p-;LbIs absent, or is-CO-, -NH-, -COO-or-NH-SO2Or is:
wherein R 'and R' are each independently- (CH)2)p-O-CO-or- [ CH2CH2-O]q-(CH2)p-O-CO-, with the dotted line representing LbAnd LaPosition of connection, wavy line LbAnd L2The location of the connection;
L2is a peptide that can be recognized and hydrolyzed by enzymes in the pathological environment;
R2is an optionally substituted alkanediamine group, or is p-aminobenzyloxy or a derivative thereof;
d represents a drug molecule covalently linked to the remainder of the compound of formula I through the oxygen in its own hydroxyl group or the nitrogen in an amine group;
each p is independently an integer from 1 to 4; and
each q is independently an integer from 1 to 8.
In a second aspect, the present invention provides an antibody drug conjugate having a structure represented by formula III below:
Ab-[X-R1’-L1-L2-R2-D]m (III)
in the formula:
ab is an antibody or antigen-binding fragment thereof, bound by X and R1' covalently linked;
x is a free amino group of a thiol group or a lysine group in a cysteine residue of the antibody or the antigen-binding fragment thereof and R1' group obtained after carrying out coupling reaction;
L1、L2、R2and D is as described herein for any embodiment of formula I;
R1' is a divalent group obtained by removing 1 or 2 Br from a group of the formula:
in the formula, R6Is bromomethyl, i.e. CH2Br-, o is 1 or 2, the wavy line represents1The connection position of (a);
m is a number between 1 and 8.
In a third aspect, the invention provides a pharmaceutical composition comprising an antibody drug conjugate according to any one of the embodiments herein and a pharmaceutically acceptable carrier.
In a fourth aspect, the present invention provides the use of a compound according to any one of the embodiments herein in the preparation of an antibody drug conjugate, and the use of an antibody drug conjugate according to any one of the embodiments herein in the preparation of a medicament for the treatment or prevention of cancer.
The detailed description and preferred versions of each aspect of the present disclosure are described in detail in various portions of this application.
Drawings
FIG. 1: nuclear magnetic hydrogen spectrum of compound 1.
FIG. 2: nuclear magnetic hydrogen spectrum of compound 2.
FIG. 3: nuclear magnetic hydrogen spectrum of compound 3.
FIG. 4: nuclear magnetic hydrogen spectrum of compound 4.
FIG. 5: nuclear magnetic hydrogen spectrum of compound 7.
FIG. 6: HIC map of LN 401-20-1.
FIG. 7: SEC profile of LN 401-20-1.
FIG. 8: HIC map of LN 401-20-2.
FIG. 9: SEC profile of LN 401-20-2.
FIG. 10: HIC profile of LN 401-89-5.
FIG. 11: SEC profile of LN 401-89-5.
FIG. 12: HIC profile of LN 401-89-6.
FIG. 13: SEC profile of LN 401-89-6.
FIG. 14: HIC profile of LN 401-88-5.
FIG. 15: SEC profile of LN 401-88-5.
FIG. 16: HIC map of LN 401-31-1.
FIG. 17: SEC profile of LN 401-31-1.
FIG. 18: HIC profile of LN 401-31-2.
FIG. 19: SEC profile of LN 401-31-2.
FIG. 20: HIC profile of LN 401-90-5.
FIG. 21: SEC profile of LN 401-90-5.
FIG. 22: HIC profile of LN 401-90-6.
FIG. 23: SEC profile of LN 401-90-6.
FIG. 24: HIC profile of LN 401-90-4.
FIG. 25: SEC profile of LN 401-90-4.
FIG. 26: dose response curves of anti-CD 25 ADC after 5 days of treatment of SU-DHL-1, Karpas 299T, HDLM-2 and L-540 and CD25 negative (-) expressing CD25 (+).
FIG. 27 is a schematic view showing: dose response curves of anti-HER 2 ADC on human tumor cells expressing (+) SKBr-3 and HCC1954 and HER2 negative (-) MDA-MB-468 after 5 days of treatment.
Detailed Description
It is to be understood that within the scope of the present invention, the above-described technical features of the present invention and the technical features described in detail below (e.g., the embodiments) may be combined with each other to constitute a preferred embodiment.
The invention aims to provide a drug conjugate based on bromomethylpyrazine and an antibody drug conjugate obtained by covalently linking the bromomethylpyrazine and an antibody. Compared with the coupling method of the bis-bromomethylbenzopyrazine of WO2013/173391 and CN104379168B, the coupling method of the invention has different reactivity, the hydrophilicity of the pyrazine part is better than that of the benzopyrazine, and the corresponding synthesis and coupling are simpler and easier to control.
Term(s) for
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs. All patents, patent applications, and publications cited herein are incorporated by reference in their entirety unless otherwise indicated.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the subject matter claimed. In this application, the use of the singular also includes the plural unless specifically stated otherwise. It must be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. It should also be noted that the use of "or", "or" means "and/or" unless stated otherwise. Furthermore, the term "comprising" as well as other forms, such as "includes," "including," and "containing," are not limiting and can be open, semi-closed, and closed. In other words, the term also includes the meaning of "consisting essentially of …," or "consisting of ….
Definitions for the terms of the standardization sector can be found in the literature references including Carey and Sundberg "ADVANCED ORGANIC CHEMISTRY 4TH ED." Vols.A (2000) and B (2001), Plenum Press, New York. Unless otherwise indicated, conventional methods within the skill of the art are employed, such as mass spectrometry, NMR, IR and UV/VIS spectroscopy, and pharmacological methods. Unless a specific definition is set forth, the terms used herein in the pertinent description of analytical chemistry, organic synthetic chemistry, and pharmaceutical chemistry are known in the art. Standard techniques can be used in chemical synthesis, chemical analysis, pharmaceutical preparation, formulation and delivery, and treatment of patients. For example, the reaction and purification can be carried out using the instructions of the kit from the manufacturer, or according to the methods known in the art or the instructions of the present invention. The techniques and methods described above can generally be practiced according to conventional methods well known in the art, as described in various general and more specific documents referred to and discussed in this specification. In the present specification, groups and substituents thereof may be selected by one skilled in the art to provide stable moieties and compounds.
When a substituent is described by a general formula written from left to right, the substituent also includes chemically equivalent substituents obtained when the formula is written from right to left. For example, -CH2O-is equivalent to-OCH2-。
Certain chemical groups defined herein are preceded by a shorthand notation to indicate the total number of carbon atoms present in the group. For example, C1-C6 alkyl refers to an alkyl group as defined below having a total of 1 to 6 carbon atoms. The total number of carbon atoms in the shorthand notation excludes carbons that may be present in a substituent of the group.
In addition to the foregoing, the following terms, when used in the specification and claims of this application, have the meanings indicated below, unless otherwise specifically indicated.
In the present application, the term "halogen" refers to fluorine, chlorine, bromine or iodine.
"hydroxy" means an-OH group.
"hydroxyalkyl" refers to an alkyl group as defined below substituted with a hydroxyl group (-OH).
"carbonyl" refers to a-C (═ O) -group.
"nitro" means-NO2。
"cyano" means-CN.
"amino" means-NH2。
"carboxyl" means-COOH.
"carbonitrideamino" refers to-CH2-NH-。
In the present application, "alkyl" as a group or as part of another group refers to a fully saturated straight or branched hydrocarbon chain radical consisting only of carbon and hydrogen atoms, having, for example, from 1 to 10 (preferably from 1 to 8, more preferably from 1 to 6) carbon atoms, and being attached to the rest of the molecule by a single bond. Alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2-dimethylpropyl, n-hexyl, heptyl, 2-methylhexyl, 3-methylhexyl, octyl, nonyl, decyl, and the like. In some embodiments, the alkyl group is a C1-C4 alkyl group.
In the present application, "alkenyl" as a group or as part of another group refers to a straight or branched hydrocarbon chain group consisting of only carbon and hydrogen atoms, containing at least one double bond, having, for example, 2 to 10 (preferably 2 to 8, more preferably 2 to 6, more preferably 2 to 4) carbon atoms, and connected to the rest of the molecule by a single bond. Alkenyl groups include, but are not limited to, ethenyl, propenyl, allyl, but-1-enyl, but-2-enyl, pent-1, 4-dienyl, and the like.
In the present application, "alkynyl" as a group or as part of another group refers to a straight or branched hydrocarbon chain group consisting solely of carbon and hydrogen atoms, containing at least one triple bond, having, for example, from 2 to 10 (preferably from 2 to 8, more preferably from 2 to 6, more preferably from 2 to 4) carbon atoms, and being attached to the rest of the molecule by a single bond. Alkynyl groups include, but are not limited to, ethynyl, propynyl, and the like.
As used herein, "alkylene", "alkenylene" and "alkynylene" refer to monovalent alkyl, alkenyl or alkynyl groups that are divalent radicals formed by the loss of 1 hydrogen, such as-CH2-、-CH2CH2-、-CH2CH=CH-、-CH2C≡CCH2-and the like.
In this application, "cycloalkyl" as a group or as part of another group refers to a stable nonaromatic monocyclic hydrocarbon radical consisting only of carbon and hydrogen atoms. The number of ring carbon atoms of the cycloalkyl group is usually 3 to 8. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
In this application, "heterocyclyl" as a group or part of another group refers to a stable 5-to 10-membered non-aromatic cyclic group consisting of 2 to 14 carbon atoms (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 carbon atoms) and 1 to 6 heteroatoms selected from nitrogen, oxygen, and sulfur. Unless otherwise specifically indicated in the specification, a heterocyclic group may be a monocyclic or bicyclic ring system. The heterocyclyl group may be partially or fully saturated. The heterocyclic group may be attached to the rest of the molecule via a carbon atom or a heteroatom and by a single bond. Examples of heterocyclyl groups include, but are not limited to: azetidinyl, pyrrolidinyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, thiomorpholinyl, pyranyl, tetrahydropyranyl, thiopyranyl, tetrahydrofuranyl, oxazinyl, dioxolanyl, tetrahydroisoquinolinyl, decahydroisoquinolinyl, imidazolinyl, imidazolidinyl, quinolizinyl, thiazolidinyl, isothiazolidinyl, isoxazolidinyl, dihydroindolyl, octahydroindolyl, octahydroisoindolyl, pyrazolidinyl, and the like.
In this application, "aryl" as a group or as part of another group means a conjugated hydrocarbon ring system group having 6 to 14 carbon atoms (preferably having 6 to 10 carbon atoms, e.g., 6, 7, 8, 9, or 10 carbon atoms). The aryl group may be a monocyclic or bicyclic ring system. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, and the like.
In the present application, "aralkyl" refers to an alkyl group as defined above substituted with an aryl group as defined above.
In this application, "heteroaryl" as a group or part of another group means a 5-to 16-membered, preferably 5-to 10-membered conjugated ring system group having 1 to 15 carbon atoms (preferably 1 to 10 carbon atoms, e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms) and 1 to 6 heteroatoms selected from nitrogen, oxygen and sulfur in the ring. Unless otherwise specifically indicated in the specification, a heteroaryl group may be a monocyclic, bicyclic, tricyclic, or higher ring system. Examples of heteroaryl groups include, but are not limited to, thienyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzimidazolyl, benzopyrazolyl, indolyl, furyl, pyrrolyl, triazolyl, tetrazolyl, triazinyl, indolizinyl, isoindolyl, indazolyl, isoindolyl, purinyl, quinolyl, isoquinolyl, diazonaphthyl, naphthyridinyl, quinoxalinyl, pteridinyl, carbazolyl, carbolinyl, phenanthridinyl, phenanthrolinyl, acridinyl, phenazinyl, isothiazolyl, benzothiazolyl, pyrrolopyridyl, benzopyrolyl, benzothienyl, oxazolyl, cinnolinyl, quinazolinyl, thiophenyl, indolizinyl, orthophenanthrolinyl, isoxazolyl, phenoxazinyl, phenothiazinyl, and the like.
In the present application, the groups may be optionally substituted. "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not. For example, "optionally substituted aryl" means that the aryl group is substituted or unsubstituted, and the description includes both substituted and unsubstituted aryl groups. The "optional" substituents described in the claims and the description section of this invention include, but are not limited to, one or more of alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloepoxy, haloalkenyl, haloalkynyl, cyano, cycloalkyl-O-, nitro, amino, optionally substituted amino, alkoxy, cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl and optionally substituted heterocyclyl. In preferred embodiments, substituents include, but are not limited to, one or more of C1-C6 alkyl, haloalkyl, cycloalkyl, amino, C1-C6 alkyl substituted amino, halogen, cyano, C3-C8 cycloalkyl-O-, aryl, and heteroaryl. In the present application, when substituted, the number of substituents may be 1 to 5, such as 1 to 3, depending on the structure of the group being substituted. For example, phenyl may be substituted with 1 to 3 substituents selected from C1-C6 alkoxy, C3-C8 cycloalkyl-O-, halo and amino.
It will also be appreciated by those skilled in the art that in the processes described below, the functional groups of the intermediate compounds may need to be protected by suitable protecting groups. Such functional groups include hydroxyl, amino, mercapto and carboxylic acid. Suitable hydroxy protecting groups include trialkylsilyl or diarylalkylsilyl groups (e.g.tert-butyldimethylsilyl, tert-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, and the like. Suitable protecting groups for amino, amidino and guanidino include t-butyloxycarbonyl, benzyloxycarbonyl and the like. Suitable thiol protecting groups include-C (O) -R "(where R" is alkyl, aryl or aralkyl), p-methoxybenzyl, trityl and the like. Suitable carboxyl protecting groups include alkyl, aryl or aralkyl esters.
Protecting groups may be introduced and removed according to standard techniques known to those skilled in the art and as described herein. The use of protecting Groups is described in detail in Greene, T.W. and P.G.M.Wuts, Protective Groups in organic Synthesis, (1999),4th Ed., Wiley. In some embodiments, the protecting group herein is an amino protecting group, such as Boc (tert-butyloxycarbonyl). The protecting group may also be a polymeric resin.
I. Drug conjugates
Provided herein is a drug modified or conjugated with bromomethylpyrazine derivatives. Specifically, the drug conjugate of the present invention has a structure represented by the following formula I:
R1-L1-L2-R2-D (I)
in the formula (I), the compound is shown in the specification,
R1a group which is reactive with a thiol group in a cysteine residue or a free amino group of lysine in a polypeptide to thereby attach the drug conjugate of formula I to the polypeptide;
L1is-La-Lb-, wherein LaIs C1-C6 alkylene, C2-C6 alkenylene, C2-C6 alkynylene or- (CH)2)p-CONH-[CH2CH2-O]q-(CH2)p-;LbIs absent, or is-CO-, -NH-, -COO-or-NH-SO2Or is:
wherein R 'and R' are each independently- (CH)2)p-O-CO-or- [ CH2CH2-O]q-(CH2)p-O-CO-, with the dotted line representing LbAnd LaPosition of connection, wavy line LbAnd L2The location of the connection;
L2is a peptide that can be recognized and hydrolyzed by enzymes in the pathological environment;
R2is an optionally substituted alkanediamine group, or is p-aminobenzyloxy or a derivative thereof;
d represents a drug molecule covalently linked to the remainder of the compound of formula I through the oxygen in its own hydroxyl group or the nitrogen in an amine group;
each p is independently an integer from 1 to 4; and
each q is independently an integer from 1 to 8.
Preferably, in formula I, R1Selected from any of the following structural formulas:
in the formula, R6Is bromomethyl, i.e. CH2Br-, o is 1 or 2, the wavy line represents1The connection position of (2).
Further preferably, R1Selected from the following groups:
wherein the wavy line represents the relationship L1The location of the connection.
Preferably, in formula I, LaIs C1-C6 alkylene or- (CH)2)p-CONH-[CH2CH2-O]q-(CH2)p-. In a specific embodiment, LaIs- (CH)2)3-CONH-[(CH2)2-O]4-(CH2)2-。
Preferably, in formula I, L1Through LbAnd L2Covalent attachment; preferably, LbAnd L2Form an amide group therebetween. Preferably, Lbis-CO-or
In some preferred embodimentsIn the embodiment, L1Is: - (CH)2)3-CONH-[(CH2)2-O]4-(CH2)2-CO-、*-(CH2)3-CO-、*-(CH2)5-CO-or- (CH)2)3-CO-N(-CH2CH2-OCO-)2Indicates with R1The connection position of (2).
In formula I, preferably, L2The peptide is dipeptide, tripeptide, tetrapeptide or pentapeptide. In one or more embodiments, the amino acid residues in the peptide are selected from the group consisting of: one or more of valine, ornithine, lysine, serine, glycine, and citrulline. In one or more embodiments, the peptide is Val-Cit, Val-Orn, Val-Lys, Ser-Val-Lys, Gly-Val-Lys, Ser-Val-Cit, Gly-Gly-Gly-Val-Lys, Gly-Gly, or Gly-Gly-Val-Lys. In a preferred embodiment, the peptide is Val-Cit, Gly-Gly or Val-Lys.
Preferably, one or more amino acid residues in the peptide are modified with phosphorylcholine groups. Exemplary phosphorylcholine group-modified amino acids are shown in formula II below:
R8-L3-N(R9)-R10 (II)
in the formula, R8Is a phosphorylcholine group; n represents a nitrogen atom on an amino acid molecule; r9Is H, C1-C4 alkyl or-L3-a phosphorylcholine group; each L3Independently is a linking group; r10Represents the remainder of the amino acid molecule other than the N atom shown, said remainder being optionally protected by a protecting group.
The phosphorylcholine group may be represented by the formula:
wherein the wavy line represents the phosphorylcholine group and L3The location of the connection.
Each L3Independently is represented by-Lc-Ld-, wherein LcSelected from C1-C6 alkylene, C2-C6 alkenylene or C2-C6 alkynylene; l isdIs absent, or is carbonyl, ester (-COO-), -O-SO2-or-NH-SO2-; preferably, LdAbsent or as a carbonyl group; preferably, L3Through Ld(ii) is covalently linked to the N; preferably, LdAnd the N shown forms an amide group or a carbonitrideamino group (-CH)2-NH-); preferably, each L3Independently is a C1-C6 alkylene group or a C1-C6 alkylenecarbonyl group.
R10The amino acid molecule is selected from: glycine, alanine, valine, leucine, isoleucine, methionine, proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine, histidine, selenocysteine, pyrrolysine and ornithine; preferably, the amino acid molecule is selected from: lysine, ornithine, valine, tyrosine, glutamine, alanine, arginine, asparagine, leucine, isoleucine, threonine, serine, phenylalanine, valine, and glycine; more preferably, the amino acid molecule is selected from: valine, ornithine, lysine, serine, glycine and citrulline. More preferably, the amino acid molecule is selected from: ornithine, lysine, serine and glycine.
The "N" in formula II is not a ring nitrogen atom on an aryl, heteroaryl or heterocyclyl group in the amino acid molecule. The "N" may be the nitrogen atom in the amino acid molecule used to form the peptide bond, or may be the nitrogen atom on the free amino group present in the amino acid molecule.
In some preferred embodiments, the peptide is Val-Lys, wherein the nitrogen of the free amino group on the side chain of Lys is modified with a phosphorylcholine group. Further preferably, in said phosphorylcholine-modified Lys, L3is-CH2-CO-,R9Is hydrogen, L3Forming an amide group with the nitrogen of the free amino group on the Lys side chain.
For more details on phosphorylcholine-modified amino acids and peptides containing phosphorylcholine-modified amino acids that can be recognized and hydrolyzed by enzymes in the pathological environment, reference may be made to CN 202110303888.6, the entire content of which is incorporated herein by reference. Preferably, the phosphorylcholine-modified amino acid may be a compound represented by any one of LN001 to LN010 and LN012 to LN025 disclosed in CN 202110303888.6; in the peptide which is recognized and hydrolyzed by an enzyme in a pathological environment, the amino acid residue may be selected from: one or more of valine, ornithine, lysine, serine, glycine, and citrulline; the phosphorylcholine group-modified amino acid residue in the peptide is selected from: one or more of ornithine, lysine, serine and glycine; preferably, the peptide is selected from one or more of Val-Orn, Val-Lys, Ser-Val-Lys, Gly-Val-Lys, Ser-Val-Cit, Gly-Gly-Gly-Val-Lys and Gly-Gly-Val-Lys, preferably one or more of ornithine, lysine, serine and glycine in the peptide is modified by a phosphorylcholine group.
Preferably, in formula I, the enzyme is a proteolytic enzyme, a protease, or a peptidase. In one or more embodiments, the enzyme is selected from the group consisting of: one or more of a cysteine protease, an aspartic protease, a glutamic protease, a threonine protease, a gelatinase, a metalloprotease, and an asparagine peptide cleaving enzyme. Particularly preferably, the enzyme is asparagine endopeptidase (Legumain).
Preferably, R of formula I2Wherein the p-aminobenzyloxy derivative has the following structure:
in the formula (I), the compound is shown in the specification,
R3is H, halogen, C1-C4 alkyl, C3-C8 cycloalkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkenyl, C6-14 aryl or C6-14 aryl C1-4 alkyl; preferably H or C1-C4 alkyl, more preferably H;
R4is H or C1-C4 alkyl; preferably H, methyl or ethyl;
R5is absent fromOr is-NR6-(CH2)s-NR7-CO-, wherein s is 2 or 3, R6And R7Each independently is H or C1-C4 alkyl, which indicates the position of attachment to D;
the dotted line represents R2And L2The position of the connection, the wavy line, R2The position of the connection with D.
R2The optionally substituted alkanediamine group may be represented by-NR6-(CH2)s-NR7-, where s is 2 or 3, R6And R7Each independently is H or C1-C4 alkyl.
In general, L2And R2Are connected through amide groups.
In formula I, preferably, the drug is selected from: MMAE, Duo-5, DXD, maytansine, PNU-159682(CAS No.:202350-68-3), irinotecan, camptothecin, 7-ethyl-10-hydroxycamptothecin, topotecan, fluorouracil, doxifluridine, cytarabine, etoposide, fludarabine, capecitabine, vincristine, epothilone B, paclitaxel, docetaxel, daunorubicin, epirubicin, methotrexate, gemcitabine, melphalan, nimustine, mitoxantrone, doxorubicin, and mitomycin. Preferably the drug is MMAE, maytansine, PNU-159682, camptothecin or 7-ethyl-10-hydroxycamptothecin. It will be appreciated that when the drug is covalently linked to the remainder of formula I through the nitrogen of its amine group or the oxygen of its hydroxyl group, the attachment site on the drug does not affect the biological function and activity of the drug itself. For example, the remainder of formula I may be covalently linked via an amino or hydroxyl group at a position remote from the active center, according to the known active center of these drugs.
Preferably, it is capable of reacting with R1The polypeptides that are covalently linked are polypeptides having the desired biological activity, including but not limited to enzymes and antibodies, particularly the various antibodies described herein. The antibody is preferably a monoclonal antibody.
Preferably, the compound of formula I is a compound 1-10 herein.
II.ADC
The drug conjugates of the present invention may be used to prepare Antibody Drug Conjugates (ADCs). Specifically, the present invention provides an antibody drug conjugate represented by the following formula III:
Ab-[X-R1’-L1-L2-R2-D]m (III)
in the formula:
ab is an antibody or antigen-binding fragment thereof, bound by X and R1' covalently linked;
x is a free amino group of a thiol group or a lysine group in a cysteine residue of the antibody or the antigen-binding fragment thereof and R1' group obtained after carrying out coupling reaction;
L1、L2、R2and D is as described in any one of the embodiments above;
R1' is a divalent or trivalent radical obtained by removing 1 or 2 Br from a group of the formula:
in the formula, R6Is bromomethyl, i.e. CH2Br-, o is 1 or 2, the wavy line represents1The connection position of (a);
m represents Drug-to-Antibody Ratio (DAR) and is a value between 1 and 8.
In a preferred embodiment, R1' is:
wherein the dotted line represents R1' position of attachment to Ab, wavy line means R1' and L1The location of the connection;
L1through LaAnd R1' covalent attachment, via LbAnd L2Covalently linked, wherein LaIs C1-C6 alkylene or- (CH)2)p-CONH-[CH2CH2-O]q-(CH2)p-,Lbis-CO-or
Wherein R 'and R' are each independently- (CH)2)p-O-CO-or- [ CH2CH2-O]q-(CH2)p-O-CO-, with the dotted line representing LbAnd LaPosition of connection, wavy line LbAnd L2The position of the connection, p is an integer of 1 to 4, and q is an integer of 1 to 8;
L2is Val-Cit, Val-Orn, Val-Lys, Ser-Val-Lys, Gly-Val-Lys, Ser-Val-Cit, Gly-Gly-Gly-Val-Lys, Gly-Gly or Gly-Gly-Val-Lys; preferably Val-Cit; wherein L isbAnd L2Are connected through amido; preferably, L2One or two amino acid residues in (a) are phosphorylcholine-modified amino acid residues described herein;
R2has the following structure:
in the formula, R3Is H or C1-C4 alkyl; r4Is H or C1-C4 alkyl; r5Is absent; the dotted line represents R2And L2The position of the connection, the wavy line, R2The position of the linkage to D; wherein L is2And R2Through an amide group;
d is selected from the following medicines: MMAE, Duo-5, DXD, maytansine, PNU-159682(CAS No.:202350-68-3), irinotecan, camptothecin, 7-ethyl-10-hydroxycamptothecin (SN38), topotecan, fluorouracil, doxifluridine, cytarabine, etoposide, fludarabine, capecitabine, vincristine, epothilone B, paclitaxel, docetaxel, daunorubicin, epirubicin, methotrexate, gemcitabine, melphalan, nimustine, mitoxantrone, doxorubicin, and mitomycin; preferably MMAE, maytansine, PNU-159682, camptothecin or 7-ethyl-10-hydroxycamptothecin.
Herein, "antibody" has a meaning well known in the art and includes any form of antibody having the desired biological activity, such as monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), humanized antibodies, fully human antibodies, chimeric antibodies, camelized single domain antibodies, and the like.
By "monoclonal antibody" is meant an antibody obtained from a substantially homogeneous population of antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single epitope. In contrast, conventional (polyclonal) antibody preparations typically include a large number of antibodies directed against (or specific for) different epitopes.
"full-length antibody" refers to an immunoglobulin molecule that, when naturally occurring, comprises at least four peptide chains: the two heavy (H) chains and the two light (L) chains are linked to each other by disulfide bonds. Each heavy chain consists of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region (abbreviated herein as CH). The heavy chain constant region consists of 3 domains, CH1, CH2, and CH 3. Each light chain consists of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region consists of one domain CL. The VH and VL regions can be further subdivided into Complementarity Determining Regions (CDRs) with high variability and regions that are spaced apart to be more conserved, called Framework Regions (FRs). Each VH or VL region is formed by, in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 are composed of 3 CDRs and 4 FRs arranged from amino terminus to carboxy terminus. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant region of an antibody may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component of the classical complement system (Clq).
An "antigen-binding fragment" of an antibody includes a fragment or derivative of an antibody, typically including at least one fragment of an antigen-binding region or variable region (e.g., one or more CDRs) of a parent antibody, which retains at least some of the binding specificity of the parent antibody. Examples of antibody binding fragments include, but are not limited to, Fab ', F (ab')2, and Fv fragments; a diabody; a linear antibody; single chain antibody molecules, such as sc-Fv; nanobodies and multispecific antibodies formed from antibody fragments. When the binding activity of an antigen is expressed on a molar concentration basis, the binding fragment or derivative typically retains at least 10% of its antigen binding activity. Preferably, the binding fragment or derivative retains at least 20%, 50%, 70%, 80%, 90%, 95% or 100% or more of the antigen binding affinity of the parent antibody. It is also contemplated that antigen-binding fragments of an antibody may include conservative or non-conservative amino acid substitutions (referred to as "conservative variants" or "functionally conservative variants" of the antibody) that do not significantly alter its biological activity. The term "binding compound" refers to both antibodies and binding fragments thereof.
"Single chain Fv" or "scFv" antibodies refer to antibody fragments that comprise the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. Fv polypeptides also typically comprise a polypeptide linker between the VH and VL domains that enables the scFv to form the desired structure for antigen binding. A "domain antibody" is an immunologically functional immunoglobulin fragment that contains only the variable region of a heavy chain or the variable region of a light chain. In certain instances, two or more VH regions are covalently linked to a peptide linker to form a bivalent domain antibody. The 2 VH regions of the bivalent domain antibody may target the same or different antigens. A "bivalent antibody" comprises 2 antigen binding sites. In some cases, 2 binding sites have the same antigen specificity. However, bivalent antibodies may be bispecific. "diabodies" refer to small antibody fragments having two antigen-binding sites, which fragments comprise a heavy chain variable domain (VH) linked to a light chain variable domain (VL) in the same polypeptide chain (VH-VL or VL-VH). By using a linker that is short enough not to allow pairing between two domains of the same strand, this domain is forced to pair with the complementary domain of the other strand and two antigen binding sites are created.
Preferably, in formula III, the antibody binds to R through the free amino group of the thiol group of cysteine or lysine contained in the antibody1' connected to each other. Thus, X may be an-S-group or an-NH-group.
Preferably, in formula III, the antibody can be any of a variety of antibodies or antigen-binding fragments thereof known in the art to have the desired biological activity. For example, the antibody or functional fragment thereof may be selected from: anti-Her 2 antibody, anti-EGFR antibody, anti-VEGFR antibody, anti-CD 20 antibody, anti-CD 33 antibody, anti-PD-L1 antibody, anti-PD-1 antibody, anti-CTLA-4 antibody, anti-TNF α antibody, anti-CD 28 antibody, anti-4-1 BB antibody, anti-OX 40 antibody, anti-GITR antibody, anti-CD 27 antibody, anti-b-CD 40 antibody, or anti-ICOS antibody, anti-CD 25 antibody, anti-CD 30 antibody, anti-CD 3 antibody, anti-CD 22 antibody, anti-CCR 4 antibody, anti-CD 38 antibody, anti-CD 52 antibody, anti-complement C5 antibody, anti-RSV F protein, anti-GD 2 antibody, anti-CD GITR antibody, anti-receptor lib/ICla II glycoprotein, anti-ICOS antibody, anti-IL 2R antibody, anti-LAG 3 antibody, anti-Integrin α 4 antibody, anti-lgE antibody, anti-PDGFRa antibody, anti-RANKL antibody, anti-SLAMF 7 antibody, anti-LTIGIT antibody, anti-TIM-3 antibody, anti-VEGFR 2 antibody, anti-VISTA antibody, anti-C-Met antibody, anti-BCMA antibody, anti-Claudin 18 antibody, anti-Nectin-4 antibody, anti-CD 79b antibody, and anti-Trop 2 antibody. In some embodiments, the antibody or antigen-binding fragment thereof is an anti-CD 25 antibody or anti-binding fragment thereof, or an anti-Her 2 antibody or antigen-binding fragment thereof.
The number of moieties conjugated to the antibody in formula III (DAR, i.e.the number of m) may be a number between 1 and 8, which number is generally related to the number of disulfide bonds or lysine free amino groups in the antibody, as well as to the groups involved in the conjugation reaction and the conditions of the conjugation reaction. In some embodiments, m has a value between 3 and 6. The Drug Antibody Ratio (DAR) of the ADC can be determined by one skilled in the art using methods known in the art, such as LC-MS and UV/VIS.
In a preferred embodiment, the compound of formula III is an ADC represented by LN401-20-1, LN401-20-2, LN401-89-5, LN401-89-6, LN401-88-5, LN401-31-1, LN401-31-2, LN401-90-5, LN401-90-6, and LN401-90-4 of the present invention.
Preparation method
The compounds of formulae I, II and III herein can be prepared by methods described in the examples herein. The corresponding preparation process is described below by way of example.
A compound of formula I
In the present invention, L having an ester group can be introduced by alkylation with oxygen (O) starting from appropriately substituted methylpyrazinyl alcohol or dimethylpyrazinol1Then bromine is introduced into the methyl group of methylpyrazine, and R with carboxyl is generated after degreasing1L1Intermediate, and further L2R2D or an analogue thereof to give a compound of formula I.
Preparation of ADC
The ADC of the present invention can be obtained by reducing an antibody, mixing the reduced antibody with the compound of formula I of the present invention, standing at room temperature for a sufficient time, and then separating and purifying. Methods for reducing antibodies are well known in the art. The purpose of the reduction includes reduction of disulfide bonds in the antibody to sulfhydryl groups. Suitable reducing agents include TCEP and the like. The reducing agent and the buffer system can be selected according to different antibody types.
Pharmaceutical compositions, uses and methods of treatment and prevention of disease
The present application provides a pharmaceutical composition comprising an effective amount of an ADC according to any of the embodiments of the present application and a pharmaceutically acceptable carrier. The present application also provides a method of treating or preventing a disease comprising administering to a subject in need thereof a therapeutically effective amount or a prophylactically effective amount of an ADC of the present application or a pharmaceutical composition thereof. Also provided is the use of a compound of formula I as described herein for the preparation of an ADC, and the use of an ADC as described in any of the embodiments herein for the preparation of a medicament for the treatment or prevention of a disease.
Herein, "preventing" and "prevention" includes reducing the likelihood of occurrence or worsening of a disease or disorder in a subject; the term also includes: prevention of a disease or condition occurs in a mammal, particularly when such mammal is susceptible to the disease or condition, but has not yet been diagnosed as having the disease or condition. "treatment" and other similar synonyms include the following meanings: (i) inhibiting the disease or disorder, i.e., arresting its development; (ii) alleviating the disease or condition, i.e., causing regression of the state of the disease or condition; or (iii) alleviating the symptoms caused by the disease or disorder.
Herein, "administering" refers to a method capable of delivering a compound or composition to a desired site for biological action. Methods of administration well known in the art may be used in the present invention. These methods include, but are not limited to, oral routes, via the duodenal route, parenteral injection (including intrapulmonary, intranasal, intrathecal, intravenous, subcutaneous, intraperitoneal, intramuscular, intraarterial injection or infusion), topical administration, and rectal administration. Administration techniques useful for The compounds and methods described herein are well known to those skilled in The art, for example, in Goodman and Gilman, The pharmaceutical Basis of Therapeutics, current ed.; pergamon; and Remington's, Pharmaceutical Sciences (current edition), Mack Publishing Co., Easton, Pa.
Herein, an effective amount includes both a therapeutically effective amount and a prophylactically effective amount, and refers to an amount of an ADC of the present application that, when administered to a subject, either alone or in combination with other therapeutic agents, is effective to prevent or ameliorate one or more symptoms of a disease or condition, or the development of the disease or condition. A therapeutically effective amount also refers to an amount of ADC sufficient to result in an improvement in symptoms, such as an amount that treats, cures, prevents, or ameliorates a related medical condition or increases the rate of treatment, cure, prevention, or amelioration of such a condition. The specific effective amount will depend upon a variety of factors, such as the particular disease to be treated, the physical condition of the patient, such as weight, age and sex, the duration of the treatment, the treatment being co-administered (if any), and the specific formulation employed.
A pharmaceutically acceptable carrier refers to an ingredient of a pharmaceutical formulation or composition other than the active ingredient that is not toxic to the subject. Pharmaceutically acceptable carriers include, but are not limited to, adjuvants, carriers, excipients, glidants, sweeteners, diluents, preservatives, dyes/colorants, flavoring agents, surfactants, wetting agents, dispersing agents, suspending agents, stabilizing agents, isotonicity agents, solvents, or emulsifiers. The pharmaceutical compositions of the present application can be formulated using pharmaceutically acceptable carriers well known in the art.
The pharmaceutical compositions of the present application may be formulated into various suitable dosage forms, including but not limited to tablets, capsules, injections, and the like, and may be administered by any suitable route to achieve the intended purpose. For example, it may be administered parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, transdermally, orally, intrathecally, intracranially, intranasally or externally. The dosage of the drug may depend on the age, health and weight of the patient, concurrent treatment, and frequency of treatment, etc. The pharmaceutical compositions of the present application can be administered to any subject in need thereof, e.g., a mammal, particularly a human.
Depending on the antibody or antigen-binding fragment thereof in the ADC and the drug, the pharmaceutical composition of the present application may be used to treat or prevent the corresponding disease. For example, when the drug is an anticancer drug, the pharmaceutical composition of the present application can be used to treat cancers treatable by the anticancer drug, including but not limited to bladder, brain, breast, cervix, colon-rectum, esophagus, kidney, liver, lung, nasopharynx, pancreas, prostate, skin, stomach, uterus, ovary, testis, and blood, among others. Specifically, the cancer includes bladder cancer, kidney cancer, urinary tract cancer, chorioepithelial cancer, glioblastoma multiforme, melanoma, brain cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, kidney cancer, liver cancer, lung cancer, nasopharyngeal cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, uterine cancer, ovarian cancer, testicular cancer, and leukemia. Preferably, the ADCs of the present application are used in the treatment or prevention of solid and hematological tumors, such as lung, chorioepithelial, kidney, urinary, colon, rectal, prostate, glioblastoma multiforme, ovarian, pancreatic, breast, melanoma, liver, bladder, gastric or esophageal cancer.
In some embodiments, the drug molecule in the ADC described herein is MMAE, maytansine, PNU-159682, camptothecin, or SN38, and the disease is an indication of MMAE, maytansine, PNU-159682, camptothecin, or SN38, including gastric cancer, esophageal cancer, cardiac cancer, colon cancer, rectal cancer, primary liver cancer, acute and chronic myelogenous leukemias, chorioepithelial cancer, lung cancer, and bladder cancer.
The invention will now be further illustrated by reference to specific examples, which are intended to be illustrative only and not to be limiting of the scope of the invention. Test methods without specific conditions noted in the following examples are generally performed according to conventional conditions or according to conditions recommended by the manufacturer. All percentages, ratios, or parts are by weight unless otherwise specified. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as is familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be used in the methods of the present invention. The preferred embodiments and materials described herein are intended to be exemplary only. The materials and reagents used in the examples are commercially available, for example, anti-CD 25 antibodies are available from Zhang Jiang Biotechnology, Inc., Shanghai.
Example 1: synthesis of Compound 1
Synthesis reaction formula of Compound 1
Step 1: synthesis of Compounds 1-3
Compound 1-1(4.0g, 36.33mmol, 1.0eq) was dissolved in 100mL DMF, NaI (5.4g,36.33mmol, 1.0eq) was added, compound 1-2(9.7g, 43.59mmol, 1.2eq) was added, and K was added portionwise with stirring2CO3(7.5g,54.55mol,1.5eq), after the addition was complete, the temperature was raised to 60-65 ℃ for 2 hours, the reaction was monitored by HPLC and assisted by LC-MS, indicating that Compound 1-1 was essentially absent.
The reaction mixture was cooled to room temperature, 400mL of EA was added to the reaction mixture, and the organic phase was washed with 150mL of a saturated ammonium chloride solution and 100mL of water 3 in this order. Reuse of the organic layer with anhydrous Na2SO4After drying, concentration gave about 15g of brown oil, which was purified by reverse phase preparation at medium pressure to give 4.0g of compound 1-3 as brown oil in 44% yield. (additional N-alkylated by-product 1-3-BP 3.0 g).
1H NMR(400MHz,CDCl3)δ:8.13(s,1H),7.92(s,1H),4.33(dd,J=8Hz,4Hz,2H)2.47(s,3H),2.41(t,J=8Hz,2H),2.06-2.11(m,2H),1.46(s,9H)。
MS(+)::253.46。
The preparation method comprises the following steps:
the instrument comprises the following steps: medium pressure chromatography on Biotage Isolera One;
preparing a column: trityl SW220 topical C18, 20-45 μm, 120A;
mobile phase A: water; mobile phase B: acetonitrile;
flow rate: 50 ml/min.
Time (minutes) | Gradient (B%) |
0-10 | 20% |
10-35 | 20%-43% |
35-60 | 43% |
60-75 | 43%-95% |
75-100 | 95% |
100-115 | 95%-20% |
Step 2: synthesis of Compounds 1-4
Dissolve Compound 1-3(3.0g,11.85mmol,1.0eq) in CCl4Adding NBS (2.1g,11.85mmol and 1.0eq) into 50mL, adding AIBN (1.9g,11.85mmol and 1.0eq) under the protection of nitrogen, replacing nitrogen for 3 times after the addition is finished, heating to 80 ℃ for reaction, after the reaction is carried out for 2 hours, detecting the reaction by TLC, LC-MS and HPLC, and treating the rest of raw materials with target products.
Cooling the reaction solution to about 30 ℃ of room temperature, concentrating the reaction solution in vacuum to obtain an oily crude product, adding 30mL of acetonitrile and 15mL of water, stirring for a while until the acetonitrile and the water are dissolved, preparing the mixture in a medium-pressure reverse phase manner, and freeze-drying to obtain 2.1g of a compound 1-4 dark green oily product with the yield of 54%.
1H NMR(400MHz,CDCl3)δ:8.20(s,1H),8.17(s,1H),4.56(s,2H),4.38(dd,J=8Hz,4Hz,2H),2.42(t,J=8Hz,2H),2.10(t,8Hz,2H),1.47(s,9H)。
MS(+)::331.88。
The preparation method comprises the following steps:
the instrument comprises the following steps: medium pressure chromatography on Biotage Isolera One;
preparing a column: trityl SW220 topical C18, 20-45 μm, 120A;
mobile phase A: water; mobile phase B: acetonitrile;
flow rate: 50 ml/min.
Time (minutes) | Gradient (B%) |
0-15 | 20% |
15-55 | 20%-43% |
55-90 | 43% |
90-95 | 43%-95% |
95-110 | 95% |
110-115 | 95%-20% |
And step 3: synthesis of Compounds 1-5
Dissolving the compound 1-4(1.8g, 5.43mmol, 1.0eq) in 10mL of DCM, slowly adding 2mL of trifluoroacetic acid dropwise at the temperature of 10-15 ℃ under ice bath, reacting for 3 hours at the temperature of 20-25 ℃ in water bath, detecting by LC-MS and HPLC to obtain 1.4% of the compound 1-4 after the reaction is finished, concentrating the reaction solution in vacuum, carrying the residue with 20mL of DCM 3, adding 100mL of dichloromethane into the residue, washing with 15mL of water 4, drying the organic phase with anhydrous sodium sulfate, and concentrating to obtain 1.5g of gray solid with the yield of 100%.
1H NMR(400MHz,CDCl3)δ:8.21(s,1H),8.19(s,1H),4.57(s,2H),4.42(dd,J=8Hz,4Hz,2H),2.58(dd,J=8Hz,4Hz,2H),2.17(dd,J=8Hz,4Hz,2H).
MS(+)::276.07。
And 4, step 4: synthesis of Compound 1
Compounds 1-5(50.0mg,0.1817mmol,1.0eq) and compounds 1-6(200.0mg,0.1817mmol,1.0eq) were added to a single vial, dissolved in 8mL THF, clarified, and DIC (35.0mg,0.2727mmol,1.5eq) added. After the addition is finished, reacting for 1 hour at the room temperature of 25-30 ℃, detecting the reaction by LC-MS and HPLC, generating a target product, and processing and reacting the residual raw materials. The reaction solution was concentrated in vacuo to give an oil, which was then added with 10mL acetonitrile and 10mL water, and the mixture was prepared under high pressure and lyophilized to give 90mg of Compound 1 as a white solid with a yield of 20%. MS (+): 1381.34. Process for preparation of Compound 11H NMR is shown in FIG. 1.
The preparation method comprises the following steps:
the instrument comprises the following steps: waters2487 high pressure chromatography;
preparing a column: gemini 5 μm NX-C18, 150 x 50;
mobile phase A: water; mobile phase B: acetonitrile;
flow rate: 50 ml/min.
Time (minutes) | Gradient (B%) |
0-30 | 30%-90% |
30-31 | 95% |
31-34 | 95 |
Example 2: synthesis of Compound 2
Step 1: synthesis of Compound 2-2
Compound 2-1(4.0g, 36.33mmol, 1.0eq) was dissolved in 100mL of DMF, NaI (5.4g,36.33mmol, 1.0eq) and compound 1-2(9.7g, 43.59mmol, 1.2eq) were added, and K was added portionwise with stirring2CO3(7.5g,54.55mol,1.5eq), after the addition was complete, the temperature was raised to 60-65 ℃ for 4 hours, the reaction was monitored by HPLC, and LC-MS assisted indicated that Compound 2-1 remained, but the reaction did not proceed any more, and was stoppedAnd (5) reaction treatment.
Cooling the reaction solution to room temperature, adding 200mL of EA into the reaction solution, pouring water into about 300mL of ice water, separating the solution, extracting the aqueous phase with 100mL of EA by 3, combining the organic phases, and washing the organic phase with 100mL of water by 2. Reuse of the organic layer with anhydrous Na2SO4After drying, the mixture was concentrated to give about 12g of a brown oily substance, and the brown oily substance compound 2-2(1.3g, yield 13% was purified by reverse phase at medium pressure to give 3.2g of N-alkylated by-product 2-3-BP.
1H NMR(400MHz,CDCl3)δ:8.01(d,4HZ,1H),7.97(s,1H),4.39(dd,J=8Hz,4Hz,2H),2.53(s,3H),2.44(t,J=8Hz,2H),2.12(t,J=8Hz,2H),1.47(s,9H).
MS(+)::253.40。
The preparation method comprises the following steps:
the instrument comprises the following steps: medium pressure chromatography on Biotage Isolera One;
preparing a column: trityl SW120 topical C18, 20-45 μm, 120A;
mobile phase A: water; mobile phase B: acetonitrile;
flow rate: 30 ml/min.
Time (minutes) | Gradient (B%) |
0-10 | 30% |
10-15 | 30%-45% |
15-25 | 45% |
25-30 | 45-55 |
30-45 | 55%-65% |
45-75 | 65% |
75-80 | 65%-85% |
80-85 | 85% |
Step 2: synthesis of Compounds 2-3
Compound 2-2(1.0g,3.95mmol,1.0eq) was dissolved in CCl4Adding NBS (0.7g,3.95mmol and 1.0eq) into 15mL of the mixture, adding AIBN (0.7g,3.95mmol and 1.0eq) under the protection of nitrogen, replacing the nitrogen for 3 times again after the addition is finished, heating to 80 ℃ for reaction, after the reaction is carried out for 4 hours, detecting the reaction by LC-MS and HPLC, wherein a target product exists, the raw material remains, the reaction does not proceed any more, and treating the reaction.
Cooling the reaction liquid to about 30 ℃ at room temperature, concentrating the reaction liquid in vacuum to obtain a crude product, adding 15mL of acetonitrile and 5mL of water, stirring for a moment until the acetonitrile and the water are dissolved, carrying out medium-pressure reverse phase preparation, and freeze-drying to obtain 0.7g of a compound 2-3 which is purple oily matter with the yield of 54%.
1H NMR(400MHz,CDCl3)δ:8.11(s,1H),8.09(s,1H),4.61(s,2H),4.47(dd,J=8Hz,4Hz,2H),2.48(dd,J=4Hz,8Hz,2H),2.14(dd,J=8Hz,4Hz,2H),1.47(s,9H)。
MS(+)::276.07。
The preparation method comprises the following steps:
the instrument comprises the following steps: medium pressure chromatography on Biotage Isolera One;
preparing a column: trityl SW120 topical C18, 20-45 μm, 120A;
mobile phase A: water; mobile phase B: acetonitrile;
flow rate: 30 ml/min.
Time (minutes) | Gradient (B%) |
0-10 | 30% |
10-12 | 30%-45% |
12-22 | 45% |
22-24 | 45-55 |
24-40 | 55% |
40-44 | 55%-65% |
44-74 | 65% |
74-76 | 65%-85% |
76-86 | 85% |
And step 3: synthesis of Compounds 2-4
Dissolving the compound 2-3(0.7g, 2.11mmol, 1.0eq) in 20mL of DCM, slowly adding 4mL of trifluoroacetic acid dropwise at the temperature of 10-15 ℃ under ice bath, after the addition is finished, reacting for 5 hours in water bath at 20-25 ℃, detecting by LC-MS and HPLC, and finishing the reaction, wherein about 1.5% of raw materials are remained.
The reaction was concentrated in vacuo, the residue was taken up in 15mL _ 3 of DCM, 50mL _ dichloromethane was added to the residue, washed with 10mL _ 3 of water, the organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 2-4 as a violet solid 0.5g, 86% yield.
1H NMR(400MHz,CDCl3)δ:8.125(d,J=4Hz,1H),8.08(s,1H),4.60(s,2H),4.51(d,J=4Hz,2H),2.48(d,J=8Hz,2H),2.22(d,J=8Hz,2H)。
MS(+):276.07。
And 4, step 4: synthesis of Compound 2
Adding the compounds 2-4(50.0mg,0.1817mmol,1.0eq) and the compounds 1-6(200.0mg,0.1817mmol,1.0eq) into a single-mouth bottle, adding into 8mL THF, dissolving and clarifying, adding DIC (35.0mg,0.2727mmol,1.5eq), reacting at room temperature of 25-30 ℃ for 2 hours, detecting by LC-MS and HPLC, generating the target product, and processing and reacting if the raw material is left.
And (3) concentrating the reaction solution in vacuum to obtain an oily substance, adding 10mL of acetonitrile and 10mL of water, performing medium-pressure reverse phase preparation, and performing freeze-drying to obtain 50mg of a white solid of the compound 2, wherein the yield is 27%. Process for preparation of Compound 21The H NMR is shown in FIG. 2.
MS(+):1381.34。
The instrument comprises the following steps: medium pressure chromatography on Biotage Isolera One;
preparing a column: trityl SW40 spheical C18, 20-45 μm, 120A;
mobile phase A: water; mobile phase B: acetonitrile;
flow rate: 25 ml/min.
Example 3: synthesis of Compound 3
Step 1: synthesis of Compound 3-3
Mixing compound 3-1(4.0g, 32.22mmol, 1.0eq), compound 3-2(5.2g, 32.22mmol, 1.0eq), PPh3(10.1g, 38.66mmol, 1.2eq) was dissolved in 200mL THF, the temperature was reduced to about 5 ℃ in an ice bath, DIAD (7.8g,38.66mmol, 1.2eq) was added dropwise, after completion of the addition, the mixture was allowed to react at 0-10 ℃ for 2 hours, and HPLC detection showed that the reaction of compound 3-1 was complete, the reaction mixture was concentrated to prepare sand, and EA/PE was 30/100 column min to give compound 3-3 as a yellow oil (7.5g, 88% yield).
1H NMR(400MHZ,CDCl3)δ:7.93(s,1H),4.32(dd,J=8HZ,4HZ,2H),2.45(s,3H),2.43(s,3H),2.40-2.42(m,2H),2.06-2.11(m,2H),1.47(s,9H)。
MS(+)::267.05。
Step 2: synthesis of Compounds 3-4
Dissolving the compound 3-3(2.0g,7.51mmol,1.0eq) in CCl 450 mL, adding NBS (2.8g,15.77mmol,2.1eq), adding AIBN (0.6g,7.51mmol,1.0eq) under the protection of nitrogen, after the addition is finished, replacing the nitrogen again for 3 times, heating to 75 ℃ for reaction, after the reaction is carried out for 2 hours, detecting the reaction by LC-MS and HPLC, if the target product exists, eliminating the raw material compound 3-3, and processing the reaction.
Cooling the reaction liquid to about 30 ℃ at room temperature, filtering the reaction liquid, concentrating the filtrate in vacuum to obtain a crude product, and making sand from the crude product, wherein EA/PE is 3%. Compound 3-4 was obtained as a yellow oil (1.1g, yield 34.6%).
1H NMR(400MHZ,CDCl3)δ:8.12(s,1H),4.70(s,2H),4.59(s,2H),4.41(dd,J=4Hz,8Hz,2H),2.43(t,8Hz,2H),2.10(dd,J=8Hz,4Hz,2H),1.48(s,9H)。
MS(+):369.20。
And step 3: synthesis of Compounds 3-5
Dissolving the compound 3-4(1.0g, 2.36mmol, 1.0eq) in 20mL of DCM, slowly adding 4mL of trifluoroacetic acid dropwise at the temperature of 10-15 ℃ under ice bath, after the addition is finished, reacting for 5 hours in water bath at 20-25 ℃, detecting by LC-MS and HPLC, and finishing the reaction, wherein about 1.5% of raw materials are remained.
The reaction was concentrated in vacuo, the residue was taken up in DCM 15mL _ 3, 100mL _ dichloromethane was added to the residue, washed with water 10mL _ 3, and the organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 3-5 as a violet solid (0.8g, 93% yield).
1H NMR(400MHZ,CDCl3)δ:8.13(s,1H),4.70(s,2H),4.59(s,2H),4.45(dd,J=4Hz,8Hz,2H),2.60(t,J=8Hz,2H),2.17(dd,J=8Hz,4Hz,2H),1.48(s,9H)。
MS(+):369.20。
And step 3: synthesis of Compound 3
Compounds 3-5(100.0mg,0.27mmol,1.0eq) and compounds 1-6(300.0mg,0.27mmol,1.0eq) were added to a single vial, dissolved in 20mL THF, clarified, and added PyAOP (283mg,0.54mmol,2.0eq). After the addition is finished, reacting for 2 hours at the room temperature of 20-25 ℃, detecting the reaction by LC-MS and HPLC, generating a target product, and processing and reacting the residual raw materials.
The reaction solution was concentrated in vacuo to give an oil, which was added with acetonitrile 10mL and water 10mL, prepared under high pressure in reverse phase, and lyophilized to give compound 3 as a white solid 90mg with a yield of 23%. Process for preparation of Compound 31H NMR is shown in FIG. 3.
MS(+):1473.46。
The preparation method comprises the following steps:
the instrument comprises the following steps: waters2487 high pressure chromatography;
preparing a column: gemini 5 μm NX-C18, 150 x 50;
mobile phase A: water; mobile phase B: acetonitrile;
flow rate: 50 ml/min.
Time (minutes) | Gradient (B%) |
0-30 | 10%-90% |
31-32 | 90%-95% |
32-34 | 95%-10% |
Example 4: synthesis of Compound 4
Step 1: synthesis of Compound 4-2
Adding compound 4-1(4.8g, 38.68mmol, 1.0eq), compound 1-2(10.4g, 46.41mmol, 1.2eq) and NaI (5.8g, 38.68mmol, 1.0eq) into 200mL DMF, adding K2CO3(8.0g, 58.00mmol, 1.5eq) in batches, heating to 65 ℃ for 5 hours after the addition is finished, LC-MS, HPLC detection, LND1070-F-1 completely reacting, cooling to room temperature, pouring into 300mL ice water, and EA 200mL x 3 extracting. The organic phases are combined and washed with H2O100 × 2 washes the organic phase, dries the organic phase and then column-casts sand, PE-PE: EA ═ 20:1, collects the product and concentrates to give compound 4-2 as a colorless oil (3.9g, 37% yield).
1H NMR(400MHZ,CDCl3)δ:7.76(s,1H),4.33(dd,J=8Hz,4Hz,2H),2.46(s,2H),2.44(s,2H),2.10(dd,J=8Hz,4Hz,2H),1.47(s,9H)。
MS(+):267.27。
Step 2: synthesis of Compound 4-3
Compound 4-2(3.0g,11.27mmol,1.0eq) was dissolved in CCl4Adding NBS (4.0g,22.54mmol and 2.0eq) into 120mL, adding AIBN (3.7g,55.54mmol and 2.0eq) under the protection of nitrogen, replacing nitrogen for 3 times again after the addition is finished, heating to 85 ℃ for reaction, after 2 hours of reaction, detecting by LC-MS and HPLC that a large amount of raw materials remain, supplementing NBS (3.0g,16.90mmol and 1.5eq), continuing the reaction at 85 ℃, after 2 hours of reaction, detecting by LC-MS and HPLC that a main target product is generated, and processing the reaction.
Cooling the reaction liquid to about 20 ℃ at room temperature, filtering the reaction liquid, concentrating the filtrate in vacuum to obtain a crude product, adding acetonitrile 10ml of water 5ml of the crude product, and preparing under high pressure. Freeze-drying gave compound 4-3 as a dark green oil (1.0g, 22% yield).
1H NMR(400MHZ,CDCl3)δ:8.16(s,1H),4.58(s,2H),4.55(s,2H),4.47(dd,J=8Hz,4Hz,2H),2.47(dd,J=8Hz,4Hz,2H),2.14(t,J=8Hz,2H),1.47(s,9H)。
MS(+):424.72。
The preparation method comprises the following steps:
the instrument comprises the following steps: waters 2767 high pressure chromatography;
preparing a column: gemini 5 μm NX-C18, 150 x 50;
mobile phase A: water; mobile phase B: acetonitrile;
flow rate: 50 ml/min.
Time (minutes) | Gradient (B%) |
0-30 | 10%-90% |
31-32 | 90%-95% |
32-34 | 95%-10% |
And step 3: synthesis of Compound 4-4
Dissolving the compound 4-3(1.0g, 2.36mmol, 1.0eq) in 10mL of DCM, slowly adding 3mL of trifluoroacetic acid dropwise at the temperature of 10-15 ℃ under ice bath, after the addition is finished, reacting for 4 hours in water bath at 20-25 ℃, detecting by LC-MS and HPLC, and finishing the reaction, wherein about 1% of raw materials are remained.
The reaction was concentrated in vacuo, the residue was taken up in DCM 15mL _ 3, 100mL _ dichloromethane was added to the residue, washed with water 10mL _ 3, and the organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 4-4 as a violet solid (750mg, 87% yield).
1H NMR(400MHZ,CDCl3)δ:8.17(s,1H),4.57(s,2H),4.55(s,2H),4.49(dd,J=8Hz,4Hz,2H),2.65(t,J=8Hz,2H),2.18-2.24(m,2H)。
MS(+):369.13。
And 4, step 4: synthesis of Compound 4
Adding the compounds 4-4(100.0mg,0.27mmol,1.0eq) and the compounds 1-6(300.0mg,0.27mmol,1.0eq) into a single-mouth bottle, adding 20mL THF, dissolving and clarifying, adding PyAOP (283mg,0.54mmol,2.0eq), reacting at room temperature of 20-25 ℃ for 2 hours, detecting by LC-MS and HPLC, generating the target product, remaining the raw material, and processing for reaction.
The reaction was concentrated in vacuo to give an oil, which was added to acetonitrile 10mL, water 10mL, prepared under reverse pressure and lyophilized to give compound 4 as a white solid (90mg, 23% yield). The nuclear magnetic hydrogen spectrum of compound 4 is shown in FIG. 4. MS (+): 1473.46.
The preparation method comprises the following steps:
the instrument comprises the following steps: waters high pressure chromatography;
preparing a column: gemini 5 μm NX-C18, 150 x 50;
mobile phase A: water; mobile phase B: acetonitrile;
flow rate: 50 ml/min.
Time (minutes) | Gradient (B%) |
0-30 | 10%-90% |
31-32 | 90%-95% |
32-34 | 95%-10% |
Example 5: synthesis of Compound 5
Synthesis of Compound 5-2:
compound 5-1(200mg, 0.41mmol) and HATU (233mg, 0.61mmol) were dissolved in DMF (2ml), DIPEA (105mg, 0.82mmol) was added and the reaction stirred at room temperature for 30min, Fmoc-Val-Lys-PAB-OH (373mg, 0.41mmol) was added and the reaction stirred at room temperature for 30min, LCMS indicated complete reaction of starting material. The reaction solution was purified by reverse phase under medium pressure with acetonitrile/water as a mobile phase, and lyophilized to obtain compound 5-2(256mg, 51% yield). MS: 795.4.
synthesis of Compounds 5-3:
compound 5-2(250mg) was dissolved in 5ml of DMF, and DNPC (408mg) and DIPEA (9mg) were added. The reaction was carried out at room temperature for 18 hours. The reaction solution was purified by medium pressure reverse phase, mobile phase acetonitrile/water, collected and lyophilized to give compound 5-3(180mg, yield 67%), MS: 960.4.
synthesis of Compounds 5-4:
dissolving the compound 5-3(170mg) in 2ml of DMF, sequentially adding MMAE (140mg), HOBT (16mg) and DIPEA (50mg), and adjusting the alkalinity to a pH value of 9-10. The reaction was carried out at room temperature for 16 hours. The reaction solution was purified by medium pressure reverse phase, mobile phase acetonitrile/water, collected and lyophilized to give compound 5-4(130mg, 47% yield), MS: 1538.8.
synthesis of Compounds 5-5:
compound 5-4(130mg) was dissolved in 2ml of DMF, and DEA (0.4ml) was added. The reaction was carried out at room temperature for 2 hours. The reaction solution was purified by medium pressure reverse phase, mobile phase acetonitrile/water, collected and lyophilized to give compound 5-5(80mg, yield 57%), MS: 1316.8.
synthesis of Compound 5:
compound 5-5(50mg, 0.038mmol) and compound 1-5(16mg, 0.057 mmol) were added to THF (3ml), and DIC (15mg, 0.114mmol) was added. The reaction was carried out at room temperature for 5 hours. High pressure preparation (% acetonitrile) gave the product compound 5(23mg), MS: 1572.8.
example 6: synthesis of Compound 6
The method comprises the following steps:
synthesis of Compound 6-1:
Fmoc-ADE (10g, 30.6mmol) and DNPC (18.6g, 61.2mmol) were dissolved in 100ml DMF, DIPEA (392mg, 3.04mmol) was added, the reaction was stirred at room temperature for 16 hours, TLC showed complete reaction of the starting materials, 500ml of 5% citric acid aqueous solution was added to the reaction solution, extraction was performed three times with 500ml of ethyl acetate, organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, purified over silica gel column, mobile phase ethyl acetate: petroleum ether 30:70 gave 6-1(16.7g, 84% yield).
Step two
Synthesis of Compound 6-2:
compound 6-1(143mg, 0.216mmol), HOBt (58mg, 0.433mmol) were dissolved in DMF (7ml), DIEA (112mg, 0.865mmol) was added, stirring was carried out at room temperature for 30min, and compound 5-5(570mg, 0.433mmol) was added. The reaction was carried out at room temperature for 24 hours, and no starting material remained as determined by LCMS.
Step three:
synthesis of Compounds 6-3:
3ml of DEA was added to the above reaction system, and stirred at room temperature for 1H. Medium pressure reverse phase to obtain 125mg of product, MS: 2790.6.
Step four:
synthesis of Compound 6:
compound 6-2(50mg, 0.018mmol), Compound 1-5(8mg, 0.027mmol) was added to 4ml of THF, DIC (12mg, 0.09 mmol) was added and the reaction was allowed to proceed at ambient temperature for 14 hours under high pressure to afford 15mg of Compound 6 as a product, MS: 3046.6.
Example 7: synthesis of Compound 7
The method comprises the following steps:
synthesis of Compound 7-2: mixing compound 7-1(3g, 25mmol), compound 1-2(5g,30mmol), K2CO3(5.3g,37.5mmol) was dissolved in DMF (50 ml). The temperature is raised to 65 ℃ for reaction for three hours. The TLC plate detects that a small amount of the starting material remains and the reaction is stopped. Filtering the reaction solution, adding 500ml of EA and 500ml of saturated NaCl solution, washing the organic phase twice, adding anhydrous sodium sulfate into the organic phase, drying, and evaporating to dryness to obtain a crude product of 6.14 g; normal phase preparation, 10g of silica gel sand, 80g of silica gel column, 4% EA, PE to 1.69g of Compound 7-2.
1H NMR(400MHZ,DMSO-d6)δ:7.91(d,J=8Hz,1H),7.78(d,J=8Hz,2H),7.66(t,J=8Hz,1H),7.58(t,J=8Hz,1H),4.46(t,J=8Hz,2H),2.56(s,3H),2.44(t,J=8Hz,2H),2.01-2.08(m,2H),1.39(s,9H)。MS(+):303.43。
Step two:
synthesis of Compounds 7-3: compound 7-2(1.69g, 5.6mmol), NBS (997mg, 5.6mmol) and AIBN (920mg,5.6mmol) were dissolved in CCl4(20ml), the temperature was raised to 80 ℃ to react for 1 hour. The TLC plate detects that a small amount of the starting material remains and the reaction is stopped. The reaction solution was directly evaporated to dryness to give 3.61g of crude product. Normal phase preparation, 5g of silica gel sand, 40g of silica gel column, 3% EA: PE to 500mg of compound 7-3 as product, MS: 381.29.
1H NMR(400MHZ,CDCl3)δ:8.00(d,J=8Hz,1H),7.84(t,J=8Hz,2H),7.67-7.71(m,1H),7.57-7.61(m,1H),4.73(s,2H),4.62(dd,J=8Hz,4Hz2H),,2.53(t,J=8Hz,2H),2.21(t,J=8Hz,2H)1.48(s,9H)。MS(+):382.23。
step three:
synthesis of Compounds 7-4: compound 7-3(500mg) was dissolved in 5ml DCM, and TFA (1ml) was added under ice bath. The reaction was carried out at room temperature for 16 hours. TLC plate check no raw material. Adding 50ml DCM into the reaction solution, washing with water for three times, drying the organic phase with anhydrous sodium sulfate, and directly evaporating to dryness to obtain 400mg of a compound 7-4 as a product.
1H NMR(400MHZ,CDCl3)δ:8.01(d,J=8Hz,1H),7.84(t,J=8Hz,2H),7.69(t,J=8Hz,1H),7.58-7.61(m,1H),4.72(s,2H),4.66(dd,J=8Hz,4Hz 2H),,2.71(t,J=8Hz,2H),2.25-2.32(m,2H)。MS(+):326.25。
Step four:
synthesis of compound 11: compounds 1 to 6(50mg, 0.0445mmol) and 7 to 4(21.7mg, 0.0667mmol) were dissolved in THF (3ml), and DIC (20mg,0.155mmol) was added. The reaction was carried out at room temperature for four hours. High pressure preparation (% acetonitrile) gave the product compound 12(20 mg). The nuclear magnetic hydrogen spectrum of compound 7 is shown in FIG. 5.
MS(+)::1430.22。
The preparation method comprises the following steps:
the instrument comprises the following steps: waters2487 high pressure chromatography;
preparing a column: gemini 5 μm NX-C18, 150 x 50;
mobile phase A: water; mobile phase B: acetonitrile;
flow rate: 50 ml/min.
Time (minutes) | Gradient (B%) |
0-30 | 10%-90% |
31-32 | 90%-95% |
32-34 | 95%-10% |
Example 8: synthesis of Compound 8
The method comprises the following steps:
synthesis of Compounds 8-4:
compound 8-2(PCT Patent Application No. PCT/CN2020/088565) (25.3g, 50.0mmol), compound 8-1(36.1g, 50.0mmol)) was dissolved in 240ml of DMF, DIPEA (645mg,5mmol) and HOBt (7.26g, 53.7mmol) were added via an isopiestic dropping funnel, the reaction was stirred at room temperature for 18 hours, and HPLC showed completion of the reaction of the starting material to give compound 8-3. Diethylamine (40ml) was added to the reaction solution, and stirring was continued at room temperature for 1 hour, whereupon completion of the reaction was detected by HPLC. The reaction solution was purified by medium pressure reverse phase with mobile phase acetonitrile/water, and lyophilized to obtain compound 8-4(36.5g, 81% yield). MS: 911.4.
synthesis of Compounds 8-6:
Fmoc-Peg4-COOH (200mg, 0.41mmol) and HATU (233mg, 0.61mmol) were dissolved in DMF (2ml), DIPEA (105mg, 0.82mmol) was added, the reaction was stirred at room temperature for 30min, Compound 8-4(373mg, 0.41mmol) was added, the reaction was stirred at room temperature for 30min, and LCMS indicated that the starting material was completely reacted to give Compound 8-5. Diethylamine (0.5ml) was added to the reaction solution, and stirring was continued at room temperature for 1 hour, whereupon completion of the reaction was detected by HPLC. The reaction solution was purified by reverse phase under medium pressure, mobile phase acetonitrile/water, collected and lyophilized to give 8-6(256mg, 51% yield). MS: 1158.6.
synthesis of compound 8:
compounds 8-6(60mg, 0.052mmol), compounds 1-5(57mg, 0.207mg) were dissolved in THF (3ml), and DIC (20mg,0.155mmol) was added. The reaction was carried out at room temperature for four hours. Reverse phase high pressure preparation, mobile phase acetonitrile/water. Product 8(17mg), MS: 1414.5.
example 9: synthesis of Compound 9
Compound LND1018(100mg, 0.127mmol), compound 1-5(52.65mg, 0.191mmol) was dissolved in THF (3ml) and DIC (64mg,0.508mmol) was added. Reacting for 24 hours at normal temperature. High pressure preparation (% acetonitrile) gave compound 9(10mg), MS: 1042.61.
example 10: synthesis of Compound 10
Synthesis of Compound 10-2:
compound 10-1(300mg, 0.46mmol), compound 8-1(333mg, 0.46mmol)) was dissolved in 5ml of DMF, DIPEA (129mg,1.0mmol) was added, HOBt (62g, 0.46mmol) was added, the reaction was stirred at room temperature for 18 hours, and HPLC analysis revealed that the starting material had reacted completely. The reaction solution was purified by medium pressure reverse phase, mobile phase acetonitrile/water, collected and lyophilized to give 10-2(260mg, yield 35%), MS: 1276.6.
synthesis of Compound 10-3:
compound 10-2(260mg, 0.2mmol) was dissolved in 2ml of DMF, and 0.5ml of DEA was added thereto to react at room temperature for 1 hour, and the starting material was found to react completely by HPLC. The reaction solution was purified by medium pressure reverse phase, mobile phase acetonitrile/water, collected and lyophilized to give compound 10-3(150mg, yield 45%), MS: 1054.5.
synthesis of Compound 10-4:
compound 10-3(100mg, 0.0947mmol), compound 1-5(39mg, 0.142mmol) were dissolved in THF (3ml), and DIC (48mg,0.3788mmol) was added. The reaction was carried out at room temperature for 1 hour. Reverse phase high pressure preparation gave product compound 10(17mg), MS: 1312.7.
example 11: conjugation with CD25 antibody
The CD25 antibody (0.75 mL,14.85mg/mL, 11mg in total) was added with 5.0eq TCEP (10mM), 37. mu.L, stirred at 37 ℃ for 2 hours, and 7.0eq of the corresponding compound (5mM), 44. mu.L, were added. Preserving the heat for half an hour at 37 ℃, and performing replacement and purification by a 30KDa ultrafiltration tube to finally obtain the corresponding ADC:
LN401-20-1 (CD25+ Compound 1);
LN401-20-2 (CD25+ Compound 2);
LN401-89-5 (CD25+ Compound 3);
LN401-89-6 (CD25+ Compound 4);
LN401-88-5 (CD25+ Compound 7).
HIC and SEC tests were performed according to the following table.
HIC:
SEC:
Chromatographic column | TSKgel G3000SWXL 5μm*7.8mm*300mm |
Mobile phase | 200mM PBS+10%IPA pH7.0 |
Sample volume | 10μL(50μg) |
Detection wavelength | |
Column temperature | |
25℃ | |
Flow rate of flow | 0.8ml/min |
Elution method | Equal degree |
Analysis time | 30min |
HIC and SEC profiles of LN401-20-1 are shown in FIGS. 6 and 7, respectively;
HIC and SEC profiles of LN401-20-2 are shown in FIGS. 8 and 9, respectively.
HIC and SEC profiles of LN401-89-5 are shown in FIGS. 10 and 11, respectively.
HIC and SEC profiles of LN401-89-6 are shown in FIGS. 12 and 13, respectively.
HIC and SEC profiles of LN401-88-5 are shown in FIGS. 14 and 15, respectively.
LN401-20-1 has the structure shown below, where a is CD25 antibody and the average DAR is 4.5:
LN401-20-2 has the structure shown below, where a is CD25 antibody and the average DAR is 5.2:
LN401-89-5 has the structure shown below, where a is CD25 antibody and the average DAR is 3.6:
LN401-89-6 has the structure shown below, where a is CD25 antibody and the average DAR is 4.3:
LN401-88-5 has the structure shown below, where a is CD25 antibody and the average DAR is 5.2:
example 12: and Her2 antibody conjugation
Take Her2 antibody 0.5mL, 11.33mg/mL, 5.67mg total, add 5.0eq TCEP (10mM) 19. mu.L, stir at 37 ℃ for 2 hours, add 7.0eq of the corresponding compound (5mM), 27. mu.L. Preserving the heat for half an hour at 37 ℃, and performing replacement and purification by a 30KDa ultrafiltration tube to finally obtain the corresponding ADC:
LN401-31-1(Her2+ Compound 1);
LN401-31-2(Her2+ Compound 2);
LN401-90-5(Her2+ Compound 3);
LN401-90-6(Her2+ Compound 4);
LN401-90-4(Her2+ Compound 7).
HIC and SEC were performed in the same manner as in example 12.
HIC and SEC profiles of LN401-31-1 are shown in FIGS. 16 and 17, respectively;
HIC and SEC profiles of LN401-31-2 are shown in FIGS. 18 and 19, respectively;
HIC and SEC profiles of LN401-90-5 are shown in FIGS. 20 and 21, respectively;
HIC and SEC profiles of LN401-90-6 are shown in FIGS. 22 and 23, respectively;
HIC and SEC profiles of LN401-90-4 are shown in FIGS. 24 and 25, respectively.
LN401-31-1 has the structure shown below, where B is Her2 antibody and the average DAR is 3.6:
LN401-31-2 has the structure shown below, where B is Her2 antibody and the average DAR is 4.7:
LN401-90-5 has the structure shown below, where B is Her2 antibody and the average DAR is 3.2:
LN401-90-6 has the structure shown in the following figure, where B is Her2 antibody and the average DAR is 4.0:
LN401-90-4 has the structure shown below, where B is Her2 antibody and the average DAR is 4.1:
example 13: ADC antitumor cell activity assay
Reagent
Solutions of 10mM toxin small molecules were prepared using 100% DMSO. Samples of Antibody Drug Conjugates (ADCs) were all provided in PBS.
Cell culture
The human SU-DHL-1, Daudi, SKBr-3, HCC1954 and MDA-MB-468 cancer cell lines used in the activity tests were purchased from Type Culture Collection (ATCC; Manassas, VA), U.S.A., L-540 and HDLM-2 were purchased from Liebnizz institute DSMZ (Mannheim, Germany), while Karpas 299T was purchased from Sigma (St. Louis, MO). All cell lines were cultured in RPMI-1640 medium (Gibco) supplemented with 10-20% heat-inactivated fetal bovine serum (FBS, Corning; Corning, NY, USA) based on the recommendations of ATCC or DSMZ, except that MDA-MB-468 was routinely cultured in DMEM/F:12 medium (Gibco; Waltham, MA). 5% CO at 37 deg.C2Culturing in a humidified environment.
Cell viability assay
Adherent tumor cells were harvested by non-enzymatic separation from cell dissociation reagents (Corning), and suspension cell lines were harvested by centrifugation at 300 × g for 5 min. They were seeded into 384-well clear-bottom white wall plates (875 cells per well for adherent cells and 2500 cells/well for suspension cells in 12.5 μ L of whole medium) and left to adhere at 37 ℃ for 2-4 hours. Cells were then treated with 12.5 μ L of test sample at a final concentration of 2X in duplicate, then serially diluted in complete medium, which was incubated at 37 ℃ for 120 hours. According to the use scheme of the instrument manufacturer, useCell viability assay (Promega; Madison, Wis., USA) determined inhibition of cancer cell growth. Luminescence was measured using a Tecan Spark multimode microplate reader (Tecan Group Ltd.; Switzerland Mandoff).
Data analysis
Data were normalized using Microsoft Excel (redmond, washington) with control treated with no test sample and analyzed using GraphPad Prism software (version 8; rajohn, ca, usa). The half maximal effective concentration for inhibition was derived from the dose response curve using non-linear regression analysis fitted to a 4-parameter logistic equation (EC 50).
Results
The inhibitory effect of LN401-20-1 and LN401-20-2 on each cell is shown in Table 1 below and FIG. 26. As shown in FIG. 26, LN401-20-1 and LN401-20-2 both dose-dependently inhibited cell viability of SU-DHL-1, Karpas 299T, L-540, and HDLM-2 cells expressing CD25, as well as CD25 negative Daudi cells.
The inhibitory effects of LN401-31-1 and LN401-31-2 on the following tables of human tumors are shown in Table 2 and FIG. 27.
Table 1: EC50 values of anti-CD 25 ADC in human tumor cells
Table 2: EC50 values of anti-HER 2 ADC in human tumor cells
Claims (15)
1. A compound having the structure shown in formula I:
R1-L1-L2-R2-D (I)
in the formula (I), the compound is shown in the specification,
R1selected from any of the following structural formulas:
wherein R is6Is bromomethyl, i.e. CH2Br-, o is 1 or 2, the wavy line represents1The connection position of (a);
L1is-La-Lb-, wherein LaIs C1-C6 alkylene, C2-C6 methyleneAlkenyl, C2-C6 alkynylene or- (CH)2)p-CONH-[CH2CH2-O]q-(CH2)p-;LbIs absent, or is-CO-, -NH-, -COO-or-NH-SO2Or is:
wherein R 'and R' are each independently- (CH)2)p-O-CO-or- [ CH2CH2-O]q-(CH2)p-O-CO-, with the dotted line representing LbAnd LaPosition of connection, wavy line LbAnd L2The location of the connection;
L2is a peptide that can be recognized and hydrolyzed by enzymes in the pathological environment;
R2is an optionally substituted alkanediamine group, or is p-aminobenzyloxy or a derivative thereof;
d represents a drug molecule covalently linked to the remainder of the compound of formula I through the oxygen in its own hydroxyl group or the nitrogen in an amine group;
each p is independently an integer from 1 to 4; and
each q is independently an integer from 1 to 8.
3. The compound of claim 1 or 2,
Lais C1-C6 alkylene or- (CH)2)p-CONH-[CH2CH2-O]q-(CH2)p-; preferably, LaIs- (CH)2)3-CONH-[(CH2)2-O]4-(CH2)2-;
Lbis-CO-or
Wherein L is1Through LbWith amide groups and L2Covalent attachment;
preferably, L1Is- (CH)2)3-CONH-[(CH2)2-O]4-(CH2)2-CO-、-(CH2)3-CO-、-(CH2)5-CO-or- (CH)2)3-CO-N(-CH2CH2-OCO-)2。
4. A compound according to any one of claims 1 to 3 wherein L is2The peptide is dipeptide, tripeptide, tetrapeptide or pentapeptide; preferably, the amino acid residues in the peptide are selected from: one or more of valine, ornithine, lysine, serine, glycine, and citrulline;
preferably, the peptide is Val-Cit, Val-Orn, Val-Lys, Ser-Val-Lys, Gly-Val-Lys, Ser-Val-Cit, Gly-Gly-Gly-Val-Lys, Gly-Gly or Gly-Gly-Val-Lys;
preferably, the enzyme is a proteolytic enzyme, protease or peptidase; more preferably, the enzyme is selected from: one or more of a cysteine protease, an aspartic protease, a glutamic protease, a threonine protease, a gelatinase, a metalloprotease, and an asparagine peptide cleaving enzyme.
5. The compound of claim 4, wherein one or more amino acid residues in the peptide are modified with a phosphorylcholine group; preferably, the phosphorylcholine group-modified amino acid is represented by formula II below:
R8-L3-N(R9)-R10 (II)
in the formula, R8Is a phosphorylcholine group; n represents a nitrogen atom on an amino acid molecule; r9Is H, C1-C4 alkyl or-L3-a phosphorylcholine group; each L3Independently is a linking group; r10Represents the remainder of the amino acid molecule other than the indicated N atom, said remainder being optionally protected by a protecting group;
wherein the phosphorylcholine group is represented by the following formula:
wherein the wavy line represents the phosphorylcholine group and L3The location of the connection;
preferably, each L3Independently is represented by-Lc-Ld-, wherein LcSelected from C1-C6 alkylene, C2-C6 alkenylene or C2-C6 alkynylene; l isdIs absent, or is carbonyl, ester (-COO-), -O-SO2-or-NH-SO2-; preferably, LdAbsent or as a carbonyl group; preferably, L3Through Ld(ii) is covalently linked to the N; preferably, LdAnd the N shown forms an amide group or a carbonitrideamino group (-CH)2-NH-); preferably, each L3Independently is a C1-C6 alkylene group or a C1-C6 alkylenecarbonyl group.
6. The compound of any one of claims 1-5, wherein R is2Wherein the p-aminobenzyloxy derivative has the following structure:
in the formula (I), the compound is shown in the specification,
R3is H, halogen, C1-C4 alkyl, C3-C8 cycloalkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkenyl, C6-14 aryl or C6-14 aryl C1-4 alkyl; preferably H or C1-C4 alkyl, more preferably H;
R4is H or C1-C4 alkyl; preferably H, methyl or ethyl;
R5is absent, or is-NR6-(CH2)s-NR7-CO-, wherein s is 2 or 3, R6And R7Each independently is H or C1-C4 alkyl, which indicates the position of attachment to D;
the dotted line represents R2And L2The position of the connection, the wavy line, R2The position of the linkage to D;
the optionally substituted alkanediamine group is represented by-NR6-(CH2)s-NR7-, where s is 2 or 3, R6And R7Each independently is H or C1-C4 alkyl;
preferably, L2And R2Are connected through amide groups.
7. The compound of any one of claims 1 to 6, wherein the drug is selected from the group consisting of: MMAE, Duo-5, DXD, maytansine, PNU-159682, irinotecan, camptothecin, 7-ethyl-10-hydroxycamptothecin, topotecan, fluorouracil, doxifluridine, cytarabine, etoposide, fludarabine, capecitabine, vincristine, epothilone B, paclitaxel, docetaxel, daunorubicin, epirubicin, methotrexate, gemcitabine, melphalan, nimustine, mitoxantrone, doxorubicin, and mitomycin; preferred drugs are MMAE, maytansine, PNU-159682, camptothecin or 7-ethyl-10-hydroxycamptothecin.
9. an antibody drug conjugate having the structure shown in formula III below:
Ab-[X-R1’-L1-L2-R2-D]m (III)
in the formula:
ab is an antibody or antigen-binding fragment thereof, bound by X and R1' covalently linked;
x is a free amino group of a thiol group or a lysine group in a cysteine residue of the antibody or the antigen-binding fragment thereof and R1' group obtained after carrying out coupling reaction;
L1、L2、R2and D is as described in any one of claims 1-7;
R1' is a divalent or trivalent radical obtained by removing 1 or 2 Br from a group of the formula:
in the formula, R6Is bromomethyl, i.e. CH2Br-, o is 1 or 2, the wavy line represents1The connection position of (a);
m is a number between 1 and 8.
10. The antibody drug conjugate of claim 9, wherein R is1' is:
therein, deficiency of bloodLine represents R1' position of attachment to Ab, wavy line means R1' and L1The location of the connection;
L1through LaAnd R1' covalent attachment, via LbAnd L2Covalently linked, wherein LaIs C1-C6 alkylene or- (CH)2)p-CONH-[CH2CH2-O]q-(CH2)p-,Lbis-CO-or
Wherein R 'and R' are each independently- (CH)2)p-O-CO-or- [ CH2CH2-O]q-(CH2)p-O-CO-, with the dotted line representing LbAnd LaPosition of connection, wavy line LbAnd L2The position of the connection, p is an integer of 1 to 4, and q is an integer of 1 to 8;
L2is Val-Cit, Val-Orn, Val-Lys, Ser-Val-Lys, Gly-Val-Lys, Ser-Val-Cit, Gly-Gly-Gly-Val-Lys, Gly-Gly or Gly-Gly-Val-Lys; preferably Val-Cit; wherein L isbAnd L2Are connected through amido; preferably, L2One or two of the amino acid residues in (a) are the phosphorylcholine-modified amino acid residue of claim 5;
R2has the following structure:
in the formula, R3Is H or C1-C4 alkyl; r4Is H or C1-C4 alkyl; r5Is absent; the dotted line represents R2And L2The position of the connection, the wavy line, R2The position of the linkage to D; wherein L is2And R2Through an amide group;
d is selected from the following medicines: MMAE, Duo-5, DXD, maytansine, PNU-159682, irinotecan, camptothecin, 7-ethyl-10-hydroxycamptothecin, topotecan, fluorouracil, doxifluridine, cytarabine, etoposide, fludarabine, capecitabine, vincristine, epothilone B, paclitaxel, docetaxel, daunorubicin, epirubicin, methotrexate, gemcitabine, melphalan, nimustine, mitoxantrone, doxorubicin, and mitomycin; preferably MMAE, maytansine, PNU-159682, camptothecin or 7-ethyl-10-hydroxycamptothecin.
11. The antibody drug conjugate of claim 9, wherein the antibody drug conjugate is selected from the group consisting of:
an ADC of the formula wherein a is a CD25 antibody and m has a value between 1 and 8:
an ADC of the formula wherein a is a CD25 antibody and m has a value between 1 and 8:
an ADC of the formula wherein a is a CD25 antibody and m has a value between 1 and 8:
an ADC of the formula wherein a is a CD25 antibody and m has a value between 1 and 8:
an ADC of the formula wherein a is a CD25 antibody and m has a value between 1 and 8:
an ADC of the formula wherein B is Her2 antibody and m has a value between 1 and 8:
an ADC of the formula wherein B is Her2 antibody and m has a value between 1 and 8:
an ADC of the formula wherein B is Her2 antibody and m has a value between 1 and 8:
an ADC of the formula wherein B is Her2 antibody and m has a value between 1 and 8:
an ADC of the formula wherein B is Her2 antibody and m has a value between 1 and 8:
12. the antibody drug conjugate of claim 11, wherein the antibody drug conjugate is selected from the group consisting of:
LN401-20-1 of the formula wherein a is a CD25 antibody and m is 4.5:
LN401-20-2 of formula wherein a is a CD25 antibody, and m is 5.2:
LN401-89-5 of the formula wherein a is a CD25 antibody and m is 3.6:
LN401-89-6 of formula wherein a is a CD25 antibody and m is 4.3:
LN401-88-5 of the formula wherein a is a CD25 antibody and m is 5.2:
LN401-31-1 of formula wherein B is Her2 antibody and m is 3.6:
LN401-31-2 of formula wherein B is Her2 antibody and m is 4.7:
LN401-90-5 of formula wherein B is Her2 antibody and m is 3.2:
LN401-90-6 of formula wherein B is Her2 antibody and m is 4.0:
LN401-90-4 of formula wherein B is Her2 antibody and m is 4.1:
13. a pharmaceutical composition comprising the antibody drug conjugate of any one of claims 9-12 and a pharmaceutically acceptable carrier.
14. Use of a compound according to any one of claims 1 to 8 for the manufacture of an antibody drug conjugate, and use of an antibody drug conjugate according to any one of claims 9 to 12 for the manufacture of a medicament for the treatment or prevention of cancer.
15. The use of claim 14, wherein the cancer is selected from the group consisting of: bladder cancer, kidney cancer, urinary tract cancer, chorioepithelial cancer, glioblastoma multiforme, melanoma, brain cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, kidney cancer, liver cancer, lung cancer, nasopharyngeal cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, uterine cancer, ovarian cancer, testicular cancer, and leukemia;
preferably, the drug molecule in the antibody drug conjugate is MMAE, maytansine, PNU-159682, camptothecin or 7-ethyl-10-hydroxycamptothecin, and the disease is an indication for MMAE, maytansine, PNU-159682, camptothecin or 7-ethyl-10-hydroxycamptothecin, including gastric cancer, esophageal cancer, cardiac cancer, colon cancer, rectal cancer, primary liver cancer, acute and chronic myelogenous leukemias, chorioepithelial cancer, lung cancer and bladder cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110466799.3A CN114106088A (en) | 2021-04-28 | 2021-04-28 | Bromomethylpyrazine-based drug conjugates and ADCs |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110466799.3A CN114106088A (en) | 2021-04-28 | 2021-04-28 | Bromomethylpyrazine-based drug conjugates and ADCs |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114106088A true CN114106088A (en) | 2022-03-01 |
Family
ID=80359502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110466799.3A Pending CN114106088A (en) | 2021-04-28 | 2021-04-28 | Bromomethylpyrazine-based drug conjugates and ADCs |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114106088A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114874287A (en) * | 2022-05-20 | 2022-08-09 | 联宁(苏州)生物制药有限公司 | Synthetic method of antibody coupled drug-linker LND1042 |
WO2022199237A1 (en) * | 2021-03-22 | 2022-09-29 | 联宁(苏州)生物制药有限公司 | Modified amino acids and application thereof in adc |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015155753A2 (en) * | 2015-08-10 | 2015-10-15 | Suzhou M-Conj Biotech Co., Ltd | Novel linkers and their uses in specific conjugation of drugs to a biological molecule |
CN106132431A (en) * | 2013-10-15 | 2016-11-16 | 索伦托治疗有限公司 | There is targeted molecular and the drug conjugates of two kinds of different pharmaceuticals |
WO2020035027A1 (en) * | 2018-08-17 | 2020-02-20 | 中国人民解放军军事科学院军事医学研究院 | Linker, antibody-drug conjugate including same, and use thereof |
CN111433188A (en) * | 2018-12-17 | 2020-07-17 | 荣昌生物制药(烟台)股份有限公司 | Linker for antibody drug conjugate and application thereof |
US20200347075A1 (en) * | 2017-12-15 | 2020-11-05 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Bioactive conjugate, preparation method therefor and use thereof |
JP2021006531A (en) * | 2020-09-01 | 2021-01-21 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. | Bridge linkers for conjugation of cell-binding molecule |
-
2021
- 2021-04-28 CN CN202110466799.3A patent/CN114106088A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106132431A (en) * | 2013-10-15 | 2016-11-16 | 索伦托治疗有限公司 | There is targeted molecular and the drug conjugates of two kinds of different pharmaceuticals |
WO2015155753A2 (en) * | 2015-08-10 | 2015-10-15 | Suzhou M-Conj Biotech Co., Ltd | Novel linkers and their uses in specific conjugation of drugs to a biological molecule |
US20200347075A1 (en) * | 2017-12-15 | 2020-11-05 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Bioactive conjugate, preparation method therefor and use thereof |
WO2020035027A1 (en) * | 2018-08-17 | 2020-02-20 | 中国人民解放军军事科学院军事医学研究院 | Linker, antibody-drug conjugate including same, and use thereof |
CN110835316A (en) * | 2018-08-17 | 2020-02-25 | 中国人民解放军军事科学院军事医学研究院 | Linker, antibody conjugate drug containing linker and use of linker |
CN111433188A (en) * | 2018-12-17 | 2020-07-17 | 荣昌生物制药(烟台)股份有限公司 | Linker for antibody drug conjugate and application thereof |
JP2021006531A (en) * | 2020-09-01 | 2021-01-21 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. | Bridge linkers for conjugation of cell-binding molecule |
Non-Patent Citations (2)
Title |
---|
樊代明: "《肿瘤研究前沿 第17卷》", 30 November 2017, 西安交通大学出版社, pages: 114 * |
郑志高: "磺胺-5-甲氧嘧啶酶联免疫分析试剂盒的研制与应用", 《检验检疫科学》, vol. 1, pages 57 - 62 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022199237A1 (en) * | 2021-03-22 | 2022-09-29 | 联宁(苏州)生物制药有限公司 | Modified amino acids and application thereof in adc |
CN114874287A (en) * | 2022-05-20 | 2022-08-09 | 联宁(苏州)生物制药有限公司 | Synthetic method of antibody coupled drug-linker LND1042 |
CN114874287B (en) * | 2022-05-20 | 2024-04-02 | 联宁(苏州)生物制药有限公司 | Synthesis method of antibody coupling drug-linker LND1042 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113816969B (en) | Eptification control compound, antibody drug conjugate thereof and application thereof | |
CN107428801B (en) | Hemiasterlin derivatives for coupling and therapy | |
CN113816990B (en) | Modified amino acids and their use in ADCs | |
JP2024038168A (en) | Bioactive molecule conjugates, their preparation and uses | |
CN114456186B (en) | Camptothecine derivative and ligand-drug conjugate thereof | |
CN106604927B (en) | Cytotoxic benzodiazepine derivatives | |
CN111433188B (en) | Connector for antibody drug conjugate and application thereof | |
AU2019311557A1 (en) | Effective method for manufacturing antibody-drug conjugate | |
KR20160045146A (en) | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses | |
TW201609152A (en) | Conjugates comprising cell-binding agents and cytotoxic agents | |
KR20230022211A (en) | Camptothecin drug having a highly stable hydrophilic linking unit and conjugates thereof | |
TW201705983A (en) | Conjugates of cysteine engineered antibodies | |
CN114106088A (en) | Bromomethylpyrazine-based drug conjugates and ADCs | |
CN106467575A (en) | Cysteine engineered Antibody-toxin conjugate | |
CN106866822A (en) | Cysteine engineered antibody toxin conjugate | |
CA3198230A1 (en) | Conjugate and use thereof | |
CN114569739A (en) | Antibody drug conjugates | |
CN112237634A (en) | Antibody drug conjugate, intermediate thereof, preparation method and application | |
JP6998386B2 (en) | Cysteine-modified antibody-toxin complex and its production method | |
CN109125736B (en) | Non-natural amatoxin antibody conjugate | |
WO2019191630A1 (en) | Selective reduction of antibodies | |
WO2022262789A1 (en) | Antitumor compound and use thereof | |
WO2018233572A1 (en) | Screening of fixed-point coupling sites of cysteine-modified antibody-toxin conjugate (tdc) | |
CN113813399A (en) | Camptothecin compound, antibody drug conjugate thereof and application thereof | |
WO2024067754A1 (en) | Auristatin drug with high-stability hydrophilic linking unit and conjugate thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |